<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Cuproptosis: Unraveling the Mechanisms of Copper-Induced Cell Death and Its Implication in Cancer Therapy</title>
				<funder>
					<orgName type="full">Department of Chemistry</orgName>
				</funder>
				<funder>
					<orgName type="full">Mass Ventures Funds</orgName>
				</funder>
				<funder ref="#_HFxa8FX">
					<orgName type="full">American Cancer Society</orgName>
				</funder>
				<funder>
					<orgName type="full">Lung Cancer Research Foundation</orgName>
				</funder>
				<funder>
					<orgName type="full">Manning Foundation/IALS Innovation Award</orgName>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2024-02-02">2 February 2024</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Chloe</forename><surname>Springer</surname></persName>
							<email>cospringer@umass.edu</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Biology</orgName>
								<orgName type="institution">University of Massachusetts</orgName>
								<address>
									<postCode>01003</postCode>
									<settlement>Amherst</settlement>
									<region>MA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Danish</forename><surname>Humayun</surname></persName>
							<email>dhumayun@umass.edu</email>
							<affiliation key="aff1">
								<orgName type="department">Department of Chemistry</orgName>
								<orgName type="institution">University of Massachusetts</orgName>
								<address>
									<postCode>01003</postCode>
									<settlement>Amherst</settlement>
									<region>MA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Rachid</forename><surname>Skouta</surname></persName>
							<email>rskouta@umass.edu</email>
							<idno type="ORCID">0000-0003-3324-4362</idno>
							<affiliation key="aff0">
								<orgName type="department">Department of Biology</orgName>
								<orgName type="institution">University of Massachusetts</orgName>
								<address>
									<postCode>01003</postCode>
									<settlement>Amherst</settlement>
									<region>MA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Chemistry</orgName>
								<orgName type="institution">University of Massachusetts</orgName>
								<address>
									<postCode>01003</postCode>
									<settlement>Amherst</settlement>
									<region>MA</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Cuproptosis: Unraveling the Mechanisms of Copper-Induced Cell Death and Its Implication in Cancer Therapy</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2024-02-02">2 February 2024</date>
						</imprint>
					</monogr>
					<idno type="MD5">46CED791A0BC619463543AB75B6B62F3</idno>
					<idno type="DOI">10.3390/cancers16030647</idno>
					<note type="submission">Received: 5 January 2024 Revised: 29 January 2024 Accepted: 30 January 2024</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.0" ident="GROBID" when="2024-05-25T07:17+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>cuproptosis</term>
					<term>copper-induced cell death</term>
					<term>copper ionophores</term>
					<term>oxidative stress</term>
					<term>copper homeostasis</term>
					<term>lipoylation</term>
					<term>elesclomol</term>
					<term>mitochondrial respiration</term>
					<term>cancer therapy</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Cuproptosis is a recently identified form of cell death induced by imbalanced copper levels. We aimed to explore the mechanism underlying copper-induced cell death. To achieve this, we surveyed the literature to understand the biochemical implications of cuproptosis in diseases, particularly in the context of cancer. The concept of copper ionophores, such as elesclomol and disulfiram, is highlighted as they elevate intracellular copper levels, triggering oxidative stress and ultimately leading to cell death-a potential avenue for cancer therapy. Furthermore, we will delve into the intricate relationship between copper, mitochondrial respiration, and protein lipoylation, shedding light on their connections in inducing cell death.</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.">Introduction</head><p>Copper (Cu) is one of the first metals known to be used by humans. Archaeological evidence suggests that its usage dates to 10,000 years ago by ancient civilizations in regions such as Mesopotamia, Egypt, China, and India <ref type="bibr" target="#b0">[1]</ref>. Copper was not recognized to have a role in the human body until the 19th century <ref type="bibr" target="#b1">[2]</ref>. Researchers began to understand that copper was not just a useful material but an active participant in biochemical processes <ref type="bibr" target="#b1">[2]</ref>.</p><p>Today, copper is a well-known inorganic element and ranks as the third most abundant trace element in the body after zinc and iron <ref type="bibr">[3]</ref>. Within the average adult body, copper is present within a range of 50-120 mg, with serum concentrations ranging up to 1.5 mg/L [3]. In the United States, the average daily dietary Cu intake is approximately 1 mg [3]. Copper is essential for human health as it is involved in various enzymatic processes and plays crucial roles in many biological processes <ref type="bibr" target="#b3">[4]</ref>. Despite supporting vital biologic functions, copper holds a great potential to be toxic and can lead to numerous human diseases once it is dysregulated <ref type="bibr" target="#b4">[5]</ref>. Therefore, copper's homeostatic regulation is under strict control; it is regulated through intestinal absorptive cells as well as excretion through the liver, which then releases extra Cu into bile <ref type="bibr" target="#b5">[6]</ref>.</p><p>Copper can exist in either a reduced (Cu + ) or oxidized (Cu 2+ ) state <ref type="bibr" target="#b4">[5]</ref>. Its redox properties make copper both beneficial and toxic to the cell <ref type="bibr" target="#b6">[7]</ref>. For instance, the free intracellular Cu during the transition between the Cu + and Cu 2+ states can produce hydroxyl radicals, namely, reactive oxygen species (ROS) <ref type="bibr" target="#b7">[8]</ref>. The creation of ROS can be deleterious to proteins, lipids, DNA, fats, and nucleic acids. Additionally, they can interfere with the production of iron-sulfur clusters, which are essential to many enzymes in our cells <ref type="bibr" target="#b8">[9]</ref>.</p><p>Copper-induced cell death, also known as copper toxicity or cuproptosis, describes the harmful effects that excessive copper levels induce on cellular processes <ref type="bibr" target="#b9">[10]</ref>. Cuproptosis is a novel form of cell death, and the scientific community is in the process of unraveling its intricacies. As shown in Figure <ref type="figure" target="#fig_0">1</ref>, there have been 900 publications thus far dedicated to the research of cuproptosis, highlighting the ongoing efforts to understand this novelty.</p><p>mg <ref type="bibr">[3]</ref>. Copper is essential for human health as it is involved in various enzymatic processes and plays crucial roles in many biological processes <ref type="bibr" target="#b3">[4]</ref>. Despite supporting vital biologic functions, copper holds a great potential to be toxic and can lead to numerous human diseases once it is dysregulated <ref type="bibr" target="#b4">[5]</ref>. Therefore, copper's homeostatic regulation is under strict control; it is regulated through intestinal absorptive cells as well as excretion through the liver, which then releases extra Cu into bile <ref type="bibr" target="#b5">[6]</ref>.</p><p>Copper can exist in either a reduced (Cu + ) or oxidized (Cu 2+ ) state <ref type="bibr" target="#b4">[5]</ref>. Its redox properties make copper both beneficial and toxic to the cell <ref type="bibr" target="#b6">[7]</ref>. For instance, the free intracellular Cu during the transition between the Cu + and Cu 2+ states can produce hydroxyl radicals, namely, reactive oxygen species (ROS) <ref type="bibr" target="#b7">[8]</ref>. The creation of ROS can be deleterious to proteins, lipids, DNA, fats, and nucleic acids. Additionally, they can interfere with the production of iron-sulfur clusters, which are essential to many enzymes in our cells <ref type="bibr" target="#b8">[9]</ref>.</p><p>Copper-induced cell death, also known as copper toxicity or cuproptosis, describes the harmful effects that excessive copper levels induce on cellular processes <ref type="bibr" target="#b9">[10]</ref>. Cuproptosis is a novel form of cell death, and the scientific community is in the process of unraveling its intricacies. As shown in Figure <ref type="figure" target="#fig_0">1</ref>, there have been 900 publications thus far dedicated to the research of cuproptosis, highlighting the ongoing efforts to understand this novelty.</p><p>Figure <ref type="figure" target="#fig_0">1</ref>. Annual count of cuproptosis-related publications utilizing the PubMED search engine. In 2021, the first cuproptosis-related article was published <ref type="bibr" target="#b10">[11]</ref>, cited 65 times. In 2022, Tsvetkov and colleagues introduced the concept of a distinct form of regulated cell death induced by copper, known as cuproptosis, cited 844 times. The same year saw a notable surge, with 279 publications exploring cuproptosis, followed by a continued increase in 2023 with 580 publications. As of 2024, an additional 40 publications have been dedicated to the study of cuproptosis thus far <ref type="bibr">[12]</ref>.</p><p>One of the more recent advancements in the context of copper-induced cell death is the research and development of copper ionophores. Copper ionophores are molecules to which copper attaches outside of the cell, and they subsequently shuttle it inside the cell. The recent advancements in copper ionophore molecules have made them one of the topics of interest in the development of potential copper therapies. Significant developments occurred between 2011 and 2023, as depicted in Figure <ref type="figure" target="#fig_1">2</ref>. This timeline tracks the evolution of copper ionophores, beginning with their testing and induction of cell death in One of the more recent advancements in the context of copper-induced cell death is the research and development of copper ionophores. Copper ionophores are molecules to which copper attaches outside of the cell, and they subsequently shuttle it inside the cell. The recent advancements in copper ionophore molecules have made them one of the topics of interest in the development of potential copper therapies. Significant developments occurred between 2011 and 2023, as depicted in Figure <ref type="figure" target="#fig_1">2</ref>. This timeline tracks the evolution of copper ionophores, beginning with their testing and induction of cell death in fibrosarcoma cells, to their development as a p53-regulated cell death mechanism (Figure <ref type="figure" target="#fig_1">2</ref>). Growing knowledge about copper ionophores suggests that copper-induced cell death could become a therapeutic approach for cancer. An abundance of copper can interfere with cellular membranes, trigger the production of ROS, and disrupt crucial biological functions within cells, ultimately causing cell damage and premature cell death <ref type="bibr" target="#b11">[13]</ref>.</p><p>fibrosarcoma cells, to their development as a p53-regulated cell death mechanism (Figure <ref type="figure" target="#fig_1">2</ref>). Growing knowledge about copper ionophores suggests that copper-induced cell death could become a therapeutic approach for cancer. An abundance of copper can interfere with cellular membranes, trigger the production of ROS, and disrupt crucial biological functions within cells, ultimately causing cell damage and premature cell death <ref type="bibr" target="#b11">[13]</ref>. While cuproptosis shares commonalities in proteins and lipids with other forms of cell death like apoptosis <ref type="bibr" target="#b17">[19]</ref>, ferroptosis <ref type="bibr" target="#b18">[20]</ref>, and pyroptosis <ref type="bibr" target="#b19">[21]</ref>, it also exhibits distinct molecular mechanisms that distinguish it as a distinct form of cell death <ref type="bibr">[22]</ref>. Notably, treatments with ferroptosis inhibitor (ferrostatin-1), necroptosis inhibitor (necrostatin-1), and an oxidative stress (N-acetyl cysteine) all were unsuccessful in terminating copper ionophore-induced cell death <ref type="bibr">[22]</ref>. Furthermore, cuproptosis stands out as a novel and distinct form of cell death due to its association with mitochondrial respiration and the lipoic acid (LA) pathway <ref type="bibr">[22]</ref>. A representation of these distinct characteristics is shown in Table <ref type="table" target="#tab_0">1</ref>. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cell Death Pathway Induction Mechanisms</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Main Proteins/Genes Involved</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Disease Implications</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Cuproptosis (discovered in 2022)</head><p>Disruption of copper homeostasis, and oxidative stress FDX1 <ref type="bibr" target="#b21">[23]</ref> DLAT <ref type="bibr" target="#b21">[23]</ref> DBT <ref type="bibr" target="#b21">[23]</ref> GCSH <ref type="bibr" target="#b21">[23]</ref> DLST <ref type="bibr" target="#b21">[23]</ref> LIAS <ref type="bibr" target="#b21">[23]</ref> CTR1 <ref type="bibr" target="#b21">[23]</ref> ATP7A/ATP7B <ref type="bibr" target="#b22">[24]</ref> MT <ref type="bibr" target="#b22">[24]</ref> GSH <ref type="bibr" target="#b22">[24]</ref> PDH <ref type="bibr" target="#b23">[25]</ref> PDHA1 <ref type="bibr" target="#b23">[25]</ref> PDHB <ref type="bibr" target="#b23">[25]</ref> KDH <ref type="bibr" target="#b24">[26]</ref> SLC31A1 <ref type="bibr" target="#b25">[27,</ref><ref type="bibr" target="#b26">28]</ref> LIPT1 <ref type="bibr" target="#b27">[29]</ref> Neurological diseases (e.g., Menkes and Wilson) <ref type="bibr" target="#b24">[26]</ref>. Cancer (e.g., elevated serum copper levels in oral, gallbladder, liver, breast, esophageal, pancreatic, bladder, renal, prostatic, thyroid, cervical, and lung; decreased serum copper levels in endometrial and colorectal) <ref type="bibr" target="#b9">[10,</ref><ref type="bibr" target="#b29">31]</ref>. While cuproptosis shares commonalities in proteins and lipids with other forms of cell death like apoptosis <ref type="bibr" target="#b17">[19]</ref>, ferroptosis <ref type="bibr" target="#b18">[20]</ref>, and pyroptosis <ref type="bibr" target="#b19">[21]</ref>, it also exhibits distinct molecular mechanisms that distinguish it as a distinct form of cell death <ref type="bibr">[22]</ref>. Notably, treatments with ferroptosis inhibitor (ferrostatin-1), necroptosis inhibitor (necrostatin-1), and an oxidative stress (N-acetyl cysteine) all were unsuccessful in terminating copper ionophore-induced cell death <ref type="bibr">[22]</ref>. Furthermore, cuproptosis stands out as a novel and distinct form of cell death due to its association with mitochondrial respiration and the lipoic acid (LA) pathway <ref type="bibr">[22]</ref>. A representation of these distinct characteristics is shown in Table <ref type="table" target="#tab_0">1</ref>. Disruption of copper homeostasis, and oxidative stress FDX1 <ref type="bibr" target="#b21">[23]</ref> DLAT <ref type="bibr" target="#b21">[23]</ref> DBT <ref type="bibr" target="#b21">[23]</ref> GCSH <ref type="bibr" target="#b21">[23]</ref> DLST <ref type="bibr" target="#b21">[23]</ref> LIAS <ref type="bibr" target="#b21">[23]</ref> CTR1 <ref type="bibr" target="#b21">[23]</ref> ATP7A/ATP7B <ref type="bibr" target="#b22">[24]</ref> MT <ref type="bibr" target="#b22">[24]</ref> GSH <ref type="bibr" target="#b22">[24]</ref> PDH <ref type="bibr" target="#b23">[25]</ref> PDHA1 <ref type="bibr" target="#b23">[25]</ref> PDHB <ref type="bibr" target="#b23">[25]</ref> KDH <ref type="bibr" target="#b24">[26]</ref> SLC31A1 <ref type="bibr" target="#b25">[27,</ref><ref type="bibr" target="#b26">28]</ref> LIPT1 <ref type="bibr" target="#b27">[29]</ref> DLD <ref type="bibr" target="#b28">[30]</ref> Neurological diseases (e.g., Menkes and Wilson) <ref type="bibr" target="#b24">[26]</ref>. Cancer (e.g., elevated serum copper levels in oral, gallbladder, liver, breast, esophageal, pancreatic, bladder, renal, prostatic, thyroid, cervical, and lung; decreased serum copper levels in endometrial and colorectal) <ref type="bibr" target="#b9">[10,</ref><ref type="bibr" target="#b29">31]</ref>. CAD <ref type="bibr" target="#b45">[47]</ref> Cancer (e.g., systemic breast, lung, kidney, ovary, uterus, melanoma, leukemia, and lymphomas) <ref type="bibr" target="#b46">[48]</ref>.</p><p>Autoimmune disorders (e.g., systemic lupus erythematosus, rheumatoid arthritis, and thyroiditis) <ref type="bibr" target="#b47">[49]</ref>.</p><p>Neurodegenerative diseases (e.g., Alzheimer's, Parkinson's, and Huntington's) <ref type="bibr" target="#b39">[41]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pyroptosis (discovered in 1986)</head><p>Inflammasome activation triggers caspase cascade, leading to programmed cell death Caspase-1 <ref type="bibr" target="#b48">[50]</ref> Caspase-11 <ref type="bibr" target="#b47">[49]</ref> IL-1Î² <ref type="bibr" target="#b47">[49]</ref> IL-18 <ref type="bibr" target="#b47">[49]</ref> GSDMD <ref type="bibr" target="#b49">[51,</ref><ref type="bibr" target="#b50">52]</ref> NLRP3 <ref type="bibr" target="#b51">[53]</ref> Inflammatory disease (e.g., sepsis and Crohn's) <ref type="bibr" target="#b52">[54,</ref><ref type="bibr" target="#b53">55]</ref>. Autoimmune disorders (e.g., arthritis, psoriasis, and dermatitis) <ref type="bibr" target="#b54">[56]</ref>.</p><p>Microbial infection (e.g., legionella, salmonella, and francisella) <ref type="bibr" target="#b55">[57]</ref>.</p><p>Cancer (e.g., colorectal, gastric, and hepatocellular carcinoma) <ref type="bibr" target="#b56">[58]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">Proposed Mechanisms of Cuproptosis</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1.">General Mechanisms of Cuproptosis</head><p>Many different cellular functions require copper, especially as a cofactor in enzymes to catalyze biology reactions <ref type="bibr" target="#b7">[8]</ref>. Therefore, copper is always needed inside a cell at a specific critical concentration <ref type="bibr" target="#b57">[59]</ref>. However, if the concentration of copper increases or decreases past the critical concentration, it has been shown to cause cytotoxicity in cells <ref type="bibr" target="#b7">[8]</ref>. Additionally, cells have natural homeostatic processes and functions that can bring a cell back to equilibrium if there is an accumulation or decumulation of copper in the cell. Current research efforts are trying to understand how to turn off or break through those processes in hopes of initiating cytotoxicity to cause cell death for cancer treatment.</p><p>To initiate this process, copper must first enter the cell. This can be carried out by copper ionophores which are small molecules that copper binds to be transported into the cell <ref type="bibr">[60]</ref>. There are various types of copper ionophores that shuttle copper into the cell. For example, dithiocarbonates, bis(thiosemicarbazone) ligands, 8-hydroxyquinolines, flavones, elesclomol, and disulfiram. Copper ionophores then trigger signaling cascades that are part of the cell death pathway <ref type="bibr" target="#b57">[59]</ref>. While the complete mechanism is not well understood yet, it has been pointed out that cells that depend more on mitochondrial respiration, which includes the electron transport chain, are more sensitive to copper ionophores than cells that mostly depend on glycolysis as their main energy <ref type="bibr">[22,</ref><ref type="bibr" target="#b57">59]</ref>. It is also understood that copper does not target the electron transport chain, but rather the citric acid cycle (CAC), leading to the conclusion that cuproptosis and mitochondrial respiration are linked <ref type="bibr" target="#b57">[59]</ref>.</p><p>Furthermore, genetic screenings were performed to identify the pathways associated with cuproptosis. It was concluded that copper ionophores have two targets, FDX1, which codes for a reductase, FDX1, that reduces Cu 2+ to its more toxic form, Cu + , and genes that encode parts of the lipoic acid pathway and protein targets of lipoylation, which are also the key mediators of cuproptosis <ref type="bibr">[22]</ref>. Lipoylation is a post translational modification where lipoamide is attached to a lysine residue <ref type="bibr" target="#b57">[59]</ref>. If FDX1 and the protein lipoylation process are disturbed, the regulation of copper will be limited; therefore, cytotoxicity of copper can be achieved, leading to cuproptosis. However, the exact mechanism of these genetic encoders and cuproptosis is still being explored <ref type="bibr" target="#b59">[61]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1.1.">Copper Ionophores</head><p>Copper ionophores are shuttlers that help facilitate the movement of copper into cells <ref type="bibr" target="#b8">[9]</ref>. Copper ionophores, for example, elesclomol, form a coordination complex with Cu 2+ , which is made up of coordinate covalent bonds between the copper ion and the copper ionophore <ref type="bibr">[62]</ref>. In elesclomol, there is a center into which Cu 2+ fits into and is surrounded by other molecules and ions that help to stabilize the metal ion and its charge, forming a membrane-permeable coordination complex <ref type="bibr">[62]</ref>. Once Cu 2+ enters the mitochondria from the coordination complex, it is reduced to Cu + <ref type="bibr" target="#b10">[11]</ref>. While there are many different types of copper ionophores, in this review, we will focus on only two main ionophores that have been studied in relation to cuproptosis, elesclomol and disulfiram <ref type="bibr" target="#b8">[9]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1.2.">Elesclomol</head><p>Elesclomol has been a focus of recent research since it is believed to be at the center of finding out how to induce cuproptosis <ref type="bibr">[60]</ref>. Elesclomol is a type of copper ionophore that has a hydrophilic "hole" in the center where Cu 2+ ions can bind to and enter the cell, as shown in Figure 3 <ref type="bibr" target="#b61">[63]</ref>. Elesclomol has also been proven to target cells that are more dependent on oxidative phosphorylation rather than glycolysis, meaning well-oxygenated and mitochondria-dependent cells <ref type="bibr" target="#b57">[59]</ref>. This ionophore has also proven to be a strong inhibitor for the growth of cancer cells, thus exhibiting antitumor properties <ref type="bibr">[22]</ref>.</p><p>Cancers 2024, 16, x FOR PEER REVIEW 5 of 23 Furthermore, genetic screenings were performed to identify the pathways associated with cuproptosis. It was concluded that copper ionophores have two targets, FDX1, which codes for a reductase, FDX1, that reduces Cu 2+ to its more toxic form, Cu + , and genes that encode parts of the lipoic acid pathway and protein targets of lipoylation, which are also the key mediators of cuproptosis <ref type="bibr">[22]</ref>. Lipoylation is a post translational modification where lipoamide is attached to a lysine residue <ref type="bibr" target="#b57">[59]</ref>. If FDX1 and the protein lipoylation process are disturbed, the regulation of copper will be limited; therefore, cytotoxicity of copper can be achieved, leading to cuproptosis. However, the exact mechanism of these genetic encoders and cuproptosis is still being explored <ref type="bibr" target="#b59">[61]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1.1.">Copper Ionophores</head><p>Copper ionophores are shuttlers that help facilitate the movement of copper into cells <ref type="bibr" target="#b8">[9]</ref>. Copper ionophores, for example, elesclomol, form a coordination complex with Cu 2+ , which is made up of coordinate covalent bonds between the copper ion and the copper ionophore <ref type="bibr">[62]</ref>. In elesclomol, there is a center into which Cu 2+ fits into and is surrounded by other molecules and ions that help to stabilize the metal ion and its charge, forming a membrane-permeable coordination complex <ref type="bibr">[62]</ref>. Once Cu 2+ enters the mitochondria from the coordination complex, it is reduced to Cu + <ref type="bibr" target="#b10">[11]</ref>. While there are many different types of copper ionophores, in this review, we will focus on only two main ionophores that have been studied in relation to cuproptosis, elesclomol and disulfiram <ref type="bibr" target="#b8">[9]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1.2.">Elesclomol</head><p>Elesclomol has been a focus of recent research since it is believed to be at the center of finding out how to induce cuproptosis <ref type="bibr">[60]</ref>. Elesclomol is a type of copper ionophore that has a hydrophilic "hole" in the center where Cu 2+ ions can bind to and enter the cell, as shown in Figure 3 <ref type="bibr" target="#b61">[63]</ref>. Elesclomol has also been proven to target cells that are more dependent on oxidative phosphorylation rather than glycolysis, meaning well-oxygenated and mitochondria-dependent cells <ref type="bibr" target="#b57">[59]</ref>. This ionophore has also proven to be a strong inhibitor for the growth of cancer cells, thus exhibiting antitumor properties <ref type="bibr">[22]</ref>. Introducing elesclomol into a cell triggers cell death through cuproptosis due to excess copper which elevates ROS concentrations, inducing oxidative stress <ref type="bibr" target="#b63">[65]</ref>. Oxidative stress arises from the imbalance between the production and accumulation of ROS <ref type="bibr" target="#b64">[66]</ref>. Untreated, ROS have detrimental effects on cells, causing damage to DNA, proteins, and lipids <ref type="bibr" target="#b62">[64]</ref>. ROS are formed from free radicals of oxygen and are neutralized by antioxidants to prevent cellular damage <ref type="bibr" target="#b64">[66]</ref>. Introducing elesclomol into a cell triggers cell death through cuproptosis due to excess copper which elevates ROS concentrations, inducing oxidative stress <ref type="bibr" target="#b63">[65]</ref>. Oxidative stress arises from the imbalance between the production and accumulation of ROS <ref type="bibr" target="#b64">[66]</ref>. Untreated, ROS have detrimental effects on cells, causing damage to DNA, proteins, and lipids <ref type="bibr" target="#b62">[64]</ref>.</p><p>ROS are formed from free radicals of oxygen and are neutralized by antioxidants to prevent cellular damage <ref type="bibr" target="#b64">[66]</ref>.</p><p>Elesclomol binds to Cu 2+ in the extracellular environment and transports it into the mitochondrial matrix <ref type="bibr" target="#b62">[64]</ref>. Within the matrix, Cu 2+ is reduced to Cu + by FDX1, leading to the generation of ROS <ref type="bibr" target="#b62">[64]</ref>. FDX1 further interacts with lipoyl synthase (LIAS) to facilitate the lipoylation of DLAT <ref type="bibr" target="#b65">[67]</ref>. Moreover, FDX1 regulates the binding of DLAT and copper; Cu + binds to lipoylated mitochondrial proteins, specifically DLAT, triggering proteotoxic stress, aggregation, and eventual cell death <ref type="bibr" target="#b66">[68]</ref>. Another crucial function of Cu + is to inhibit the synthesis of Fe-S clusters, essential components of key metabolic enzymes and the electron transport chain <ref type="bibr" target="#b67">[69]</ref>. The disruption of Fe-S clusters exacerbates mitochondrial dysfunction linked to cuproptosis, contributing to the cascade of events resulting in cell death <ref type="bibr" target="#b68">[70]</ref>. This mechanism of copper-induced cell death through elesclomol is shown in Figure <ref type="figure" target="#fig_5">4</ref>.</p><p>Cancers 2024, 16, x FOR PEER REVIEW 6 of 23</p><p>Elesclomol binds to Cu 2+ in the extracellular environment and transports it into the mitochondrial matrix <ref type="bibr" target="#b62">[64]</ref>. Within the matrix, Cu 2+ is reduced to Cu + by FDX1, leading to the generation of ROS <ref type="bibr" target="#b62">[64]</ref>. FDX1 further interacts with lipoyl synthase (LIAS) to facilitate the lipoylation of DLAT <ref type="bibr" target="#b65">[67]</ref>. Moreover, FDX1 regulates the binding of DLAT and copper; Cu + binds to lipoylated mitochondrial proteins, specifically DLAT, triggering proteotoxic stress, aggregation, and eventual cell death <ref type="bibr" target="#b66">[68]</ref>. Another crucial function of Cu + is to inhibit the synthesis of Fe-S clusters, essential components of key metabolic enzymes and the electron transport chain <ref type="bibr" target="#b67">[69]</ref>. The disruption of Fe-S clusters exacerbates mitochondrial dysfunction linked to cuproptosis, contributing to the cascade of events resulting in cell death <ref type="bibr" target="#b68">[70]</ref>. This mechanism of copper-induced cell death through elesclomol is shown in Figure <ref type="figure" target="#fig_5">4</ref>. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1.3.">Disulfiram</head><p>Disulfiram is another known copper ionophore that helps shuttle copper into cells. This ionophore has been proven to help in the treatment of alcoholism and suggests that it can be used for antitumor therapies <ref type="bibr" target="#b69">[71]</ref>. In addition, several studies have suggested that disulfiram can raise the potency and effects of anticancer drugs <ref type="bibr" target="#b70">[72]</ref>. Disulfiram has a known target of proteasomes and helps inhibit the proteasomal mechanism <ref type="bibr" target="#b69">[71]</ref>. Proteasomes are a series of enzymes that can break apart certain proteins through the </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1.3.">Disulfiram</head><p>Disulfiram is another known copper ionophore that helps shuttle copper into cells. This ionophore has been proven to help in the treatment of alcoholism and suggests that it can be used for antitumor therapies <ref type="bibr" target="#b69">[71]</ref>. In addition, several studies have suggested that disulfiram can raise the potency and effects of anticancer drugs <ref type="bibr" target="#b70">[72]</ref>. Disulfiram has a known target of proteasomes and helps inhibit the proteasomal mechanism <ref type="bibr" target="#b69">[71]</ref>. Proteasomes are a series of enzymes that can break apart certain proteins through the hydrolysis of peptide bonds <ref type="bibr" target="#b69">[71]</ref>. The proteasome-mediated degradation pathway is the subject of much anticancer drug therapy research. Disulfiram, when bonded with copper to form a complex, as shown in Figure <ref type="figure" target="#fig_7">5</ref>, can become a proteasome inhibitor and targets tumor cellular copper, which can lead to cell death <ref type="bibr" target="#b69">[71]</ref>.</p><p>Cancers 2024, 16, x FOR PEER REVIEW 7 of 23 hydrolysis of peptide bonds <ref type="bibr" target="#b69">[71]</ref>. The proteasome-mediated degradation pathway is the subject of much anticancer drug therapy research. Disulfiram, when bonded with copper to form a complex, as shown in Figure <ref type="figure" target="#fig_7">5</ref>, can become a proteasome inhibitor and targets tumor cellular copper, which can lead to cell death <ref type="bibr" target="#b69">[71]</ref>. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2.">Ionophores and Chelators Roles in Copper Regulation</head><p>While copper ionophores and copper chelators share similarities in their involvement in copper regulation, they are distinct compounds. Copper is an element that exists as metallic copper (Cu) and is involved in the homeostasis of biological processes, including cancer <ref type="bibr" target="#b69">[71]</ref>. Dysregulation of copper can lead to oxidative stress and cell death through cuproptosis <ref type="bibr">[22]</ref>. Copper ionophores are small molecules that form complexes with copper and transport it across the cell membrane, specifically into the mitochondria <ref type="bibr">[22]</ref>. The introduction of copper ionophores into a cell induces copper accumulation, which triggers oxidative stress and leads to cuproptosis <ref type="bibr" target="#b69">[71]</ref>. Comparatively, copper chelators are compounds that bind to copper ions and remove toxic copper from the cells to prevent its accumulation <ref type="bibr" target="#b4">[5]</ref>. These compounds help to balance copper levels within the cell to maintain homeostasis. However, as shown in Figure <ref type="figure" target="#fig_9">6</ref>, both compounds can induce copperdependent cell death, whether due to an excess or deficiency of copper. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2.">Ionophores and Chelators Roles in Copper Regulation</head><p>While copper ionophores and copper chelators share similarities in their involvement in copper regulation, they are distinct compounds. Copper is an element that exists as metallic copper (Cu) and is involved in the homeostasis of biological processes, including cancer <ref type="bibr" target="#b69">[71]</ref>. Dysregulation of copper can lead to oxidative stress and cell death through cuproptosis <ref type="bibr">[22]</ref>. Copper ionophores are small molecules that form complexes with copper and transport it across the cell membrane, specifically into the mitochondria <ref type="bibr">[22]</ref>. The introduction of copper ionophores into a cell induces copper accumulation, which triggers oxidative stress and leads to cuproptosis <ref type="bibr" target="#b69">[71]</ref>. Comparatively, copper chelators are compounds that bind to copper ions and remove toxic copper from the cells to prevent its accumulation <ref type="bibr" target="#b4">[5]</ref>. These compounds help to balance copper levels within the cell to maintain homeostasis. However, as shown in Figure <ref type="figure" target="#fig_9">6</ref>, both compounds can induce copper-dependent cell death, whether due to an excess or deficiency of copper. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.3.">Mitochondrial Respiration and Copper Ionophore Effects</head><p>Mitochondria are membrane-bound organelles located in eukaryotic cells and they play a crucial role in the production of metabolic energy <ref type="bibr" target="#b72">[74]</ref>. Copper is an essential trace element that serves as a cofactor for numerous enzymes involved in ATP synthesis in the mitochondria <ref type="bibr" target="#b72">[74]</ref>. These copper-dependent enzymes play a key role in the final stages of cellular respiration <ref type="bibr" target="#b73">[75]</ref>. Cellular respiration generates energy, also known as ATP, through the following steps: glycolysis, occurring in the cytoplasm, the tricarboxylic acid (TCA) cycle, and oxidative phosphorylation <ref type="bibr" target="#b74">[76]</ref>. Mitochondrial respiration encompasses the phases of cellular respiration that occur exclusively within the mitochondria: the TCA cycle and oxidative phosphorylation <ref type="bibr" target="#b75">[77]</ref>. Oxidative phosphorylation, the final step of cellular respiration occurring within the inner mitochondrial matrix, is responsible for the majority of ATP production in eukaryotic cells by breaking down lipids and carbohydrates to convert them to ATP <ref type="bibr" target="#b76">[78]</ref>. Recently, the novelty of copper-dependent cell death being reliant on mitochondrial respiration has been established <ref type="bibr">[22]</ref>. Copper ionophores can enhance the activity of lipoylated enzymes within the TCA cycle, pyruvate dehydrogenase (PDH) and alpha-ketoglutarate dehydrogenase (KDH). Lipoylation occurs when a small molecule called a lipoic acid attaches itself to specific enzymes, increasing their activity <ref type="bibr" target="#b77">[79]</ref>. When copper ionophores enter the cell, they affect copper homeostasis within the mitochondria and promote the attachment of lipoic acids to these enzymes, making them more active. When cells have elevated lipoylated TCA enzymes, the final products of the TCA cycle are amplified. These products include high-energy electron carriers such </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.3.">Mitochondrial Respiration and Copper Ionophore Effects</head><p>Mitochondria are membrane-bound organelles located in eukaryotic cells and they play a crucial role in the production of metabolic energy <ref type="bibr" target="#b72">[74]</ref>. Copper is an essential trace element that serves as a cofactor for numerous enzymes involved in ATP synthesis in the mitochondria <ref type="bibr" target="#b72">[74]</ref>. These copper-dependent enzymes play a key role in the final stages of cellular respiration <ref type="bibr" target="#b73">[75]</ref>. Cellular respiration generates energy, also known as ATP, through the following steps: glycolysis, occurring in the cytoplasm, the tricarboxylic acid (TCA) cycle, and oxidative phosphorylation <ref type="bibr" target="#b74">[76]</ref>. Mitochondrial respiration encompasses the phases of cellular respiration that occur exclusively within the mitochondria: the TCA cycle and oxidative phosphorylation <ref type="bibr" target="#b75">[77]</ref>. Oxidative phosphorylation, the final step of cellular respiration occurring within the inner mitochondrial matrix, is responsible for the majority of ATP production in eukaryotic cells by breaking down lipids and carbohydrates to convert them to ATP <ref type="bibr" target="#b76">[78]</ref>. Recently, the novelty of copper-dependent cell death being reliant on mitochondrial respiration has been established <ref type="bibr">[22]</ref>. Copper ionophores can enhance the activity of lipoylated enzymes within the TCA cycle, pyruvate dehydrogenase (PDH) and alpha-ketoglutarate dehydrogenase (KDH). Lipoylation occurs when a small molecule called a lipoic acid attaches itself to specific enzymes, increasing their activity <ref type="bibr" target="#b77">[79]</ref>. When copper ionophores enter the cell, they affect copper homeostasis within the mitochondria and promote the attachment of lipoic acids to these enzymes, making them more active. When cells have elevated lipoylated TCA enzymes, the final products of the TCA cycle are amplified. These products include high-energy electron carriers such as NADH and FADH. These electron carriers are crucial for ATP generation and are the reactants for oxidative phosphorylation <ref type="bibr" target="#b72">[74]</ref>. Therefore, when cells have higher levels of lipoylated TCA enzymes, potentially caused by the entry of copper ionophores, there is a greater reliance on mitochondrial respiration for energy production.</p><p>It was also shown that inhibiting the mitochondrial pyruvate carrier, which imports pyruvate from the cytosol to the mitochondrial matrix to use in glycolysis, decreased copper-induced cell death <ref type="bibr" target="#b73">[75]</ref>. This supports the crucial role that the PDH complex plays in cuproptosis and how, consequently, an increase in PDH would ultimately enhance mitochondrial respiration alongside copper-induced cell death <ref type="bibr" target="#b73">[75]</ref>. Furthermore, the disruption caused by copper ionophores leads to a higher susceptibility of these cells to undergo copper-induced cell death, making these cells that are undergoing mitochondrial respiration 1000-fold more sensitive to copper ionophores <ref type="bibr" target="#b17">[19]</ref>. As it is concluded that copper-dependent cell death is dependent on mitochondrial respiration, copper ionophores may hold potential promise as a therapeutic target for conditions where dysregulated mitochondrial function is a contributing factor.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.4.">Lipoylation</head><p>Lipoylation is a post translational modification that occurs on four metabolic enzymes: pyruvate dehydrogenase (PDH), acetoin dehydrogenase complex (AoDH), alpha ketoglutarate (KDH), and glycine cleavage system (GCV) <ref type="bibr" target="#b78">[80]</ref>. Lipoylation must occur on these proteins that are part of the larger complex for proper enzymatic function <ref type="bibr" target="#b76">[78]</ref>. For this mechanism to occur, a lipoamide is covalently attached to a lysine residue <ref type="bibr" target="#b69">[71]</ref>. Lysine is added to these proteins to ensure the proper enzymatic functions <ref type="bibr">[22]</ref>. Two of the enzymes that require lipoylation are PDH and KDH, both of which regulate the key entry points of carbon into the CAC <ref type="bibr" target="#b69">[71]</ref>. PDH is responsible for the conversion of pyruvate into acetyl-CoA during glycolysis before it enters the CAC <ref type="bibr" target="#b69">[71]</ref>. Lipoylation is crucial for these enzymes to carry out their normal functions <ref type="bibr" target="#b69">[71]</ref>.</p><p>Gene knockout screening has shown that deletion of LIAS leads to resistance to copper-induced cell death <ref type="bibr" target="#b17">[19]</ref>. In addition, it was found that more copper-selective compounds, like elesclomol and disulfiram, were non-functioning when cells were grown in conditions requiring glycolysis <ref type="bibr">[22]</ref>. Meanwhile, compounds with the increased ability to attract metal-binding compounds killed cells, without respect to the metabolic state. This result is consistent with a unique characteristic and connection of copper to mitochondrial metabolism-mediated protein lipoylation. Moreover, FDX1 is an upstream regulator of protein lipoylation. This implies that in the absence of FDX1 encoding, protein lipoylation is impeded <ref type="bibr" target="#b76">[78]</ref>. It was found that with the FDX1 knockout screening, protein lipoylation did not occur, which led to a drop in cellular respiration as the metabolism of pyruvate to acetyl-CoA could not occur, leading to a halt in cellular respiration <ref type="bibr" target="#b76">[78]</ref>. Lastly, there was an increase in the substrate, S-adenosylmethionine, of the LIAS in the lipoic acid pathway, which is further evidence of FDX1 being an upstream regulator of protein lipoylation <ref type="bibr" target="#b18">[20]</ref>.</p><p>It has been determined that copper toxicity and protein lipoylation are linked [22]; however, no clear direct mechanistic link has been identified yet. Further tests revealed that components of the enzymes requiring lipoylation were found to bind to copper, but not nickel or cobalt <ref type="bibr">[22]</ref>. Moreover, it was found that lipoylated TCA cycle proteins binding to copper resulted in a gain of function, leading to cell toxicity <ref type="bibr">[22]</ref>. That gain of function resulted in lipoylation-dependent oligomerization of DLAT, a component of one of the targets of lipoylation <ref type="bibr" target="#b79">[81]</ref>. Without lipoylation, protein folding into the quaternary structure was dysregulated, further leading to a loss of enzymatic functions in the TCA cycle <ref type="bibr" target="#b77">[79]</ref>.</p><p>Copper is a necessary element for many of the enzymatic processes within the TCA cycle to occur. Without lipoylation with copper, enzymes would not be able to function, leading to a loss of enzymatic function in cell respiration and thus to cell death.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">Copper Relevance in Health and Disease</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1.">Copper-Based Nanomaterials</head><p>Copper-based nanomaterials (CBNs) have increased in popularity amongst scientists and researchers around the world <ref type="bibr" target="#b80">[82]</ref>. Their unique properties and characteristics, particu-larly their physiochemical features and biocompatibility, make them suitable for biomedical applications such as drug stability, proper biodistribution, improved therapeutic index, and active agent delivery to the specific site <ref type="bibr" target="#b81">[83]</ref>. Moreover, CBNs are exceptionally suitable for tumor imaging, as they can make a tumor glow on images of PET, MRI, photoimaging, and CT scans <ref type="bibr" target="#b82">[84]</ref>. Tumor imaging and antitumor treatments use CBNs' strong, almost infrared absorption and photothermal features in photothermal therapy and cancer photoimaging <ref type="bibr" target="#b82">[84]</ref>. Beyond their imaging applications, copper-based nanomaterials have become instrumental in antitumor treatments with copper <ref type="bibr" target="#b82">[84]</ref>. The large surface area of CBNs proves practical for loading multiple antitumor drugs for targeted cellular entry <ref type="bibr" target="#b82">[84]</ref>. Recently, a groundbreaking platelet vesicle-coated cuprous oxide nanoparticle (Cu2O)/TBP-2 cuproptosis sensitization system (PTC) has been developed for effective tumor therapy, particularly in lung metastasis and breast cancer <ref type="bibr" target="#b83">[85]</ref>. PTC, designed with enhanced blood circulation and tumor targeting capabilities, releases copper ions and hydrogen peroxides in acidic tumor conditions <ref type="bibr" target="#b83">[85]</ref>. Light irradiation induces cuproptosis, inhibiting cancer metastasis and promoting immune response. This study presents a promising nanomedicine design for cuproptosis-based cancer treatment <ref type="bibr" target="#b83">[85]</ref>.</p><p>The inherent copper ions in CBNs trigger the production of ROS which increases the cytotoxicity within cells <ref type="bibr" target="#b82">[84]</ref>. Upon exposure to light, CBNs trigger a high accumulation of ROS which can be used for photodynamic therapy <ref type="bibr" target="#b84">[86]</ref>. In a recent study, a glucose oxidase (GOx)-engineered non-porous copper (I) 1,2,4-triazolate coordination polymer (CP) nanoplatform, denoted as GOx@[Cu(tz)], has been developed for the induction of starvation-augmented cuproptosis and synergistic photodynamic therapy <ref type="bibr" target="#b85">[87]</ref>. This design ensures that the catalytic activity of GOx remains shielded within the non-porous scaffold until triggered by glutathione (GSH) stimulation in cancer cells, facilitating targeted cancer starvation therapy <ref type="bibr" target="#b85">[87]</ref>. The resultant depletion of glucose and GSH sensitizes cancer cells to GOx@[Cu(tz)]-mediated cuproptosis, leading to the aggregation of lipoylated mitochondrial proteins <ref type="bibr" target="#b85">[87]</ref>. In vivo experiments have shown a 92.4% efficacy of tumor inhibition in athymic mice bearing bladder tumors <ref type="bibr" target="#b85">[87]</ref>. Notably, this marks the first report of a cupreous nanomaterial capable of inducing cuproptosis and implementing cuproptosis-based synergistic therapy in bladder cancer.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2.">Anticancer Therapeutic Category</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2.1.">Non-Small Cell Lung Cancer</head><p>Lung cancer is the leading cause of cancer death in the U.S. as it accounts for approximately one in five cancer deaths <ref type="bibr" target="#b86">[88]</ref>. Specifically, non-small cell lung cancer (NSCLC), which includes squamous cell carcinoma, adenocarcinoma, and large cell carcinoma, is the most common kind of lung cancer, representing 85% of all cases <ref type="bibr" target="#b87">[89]</ref>. Notably, smoking, which is a major risk factor, contributes to the formation of malignant lung tissue <ref type="bibr" target="#b88">[90]</ref>. In NSCLC, excessive copper accumulation within cancer cells has been closely linked with tumor growth and metastasis <ref type="bibr" target="#b89">[91]</ref>. Disrupting copper homeostasis with copper-binding agents like disulfiram has shown promise by enhancing the efficacy of chemotherapy drugs, such as cisplatin, through the induction of oxidative stress and inhibition of DNA mechanisms in lung cancer cells <ref type="bibr" target="#b90">[92]</ref>. Recent phase II clinical trials combining disulfiram with cisplatin and vinorelbine demonstrated improved survival rates (10 months vs. 7.1 months for non-disulfiram recipients) in newly diagnosed NSCLC patients, with two long-term survivors identified in the disulfiram group <ref type="bibr" target="#b91">[93]</ref>. This finding suggests that integrating disulfiram into NSCLC chemotherapy treatment might enhance patient survival, prompting the need for further exploration in larger-scale trials. Another study investigated the impact of disulfiram and copper on NSCLC growth. The findings suggest that the disulfiram/copper combination induces G2/M phase cell arrest and enhances sensitivity to cisplatin in NSCLC <ref type="bibr" target="#b92">[94]</ref>. Initial tests showed that disulfiram or copper separately had a limited impact on NSCLC cell proliferation. Moreover, the combination reduced NSCLC cell colony formation and lung cancer stem cell-related gene expression <ref type="bibr" target="#b93">[95]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2.2.">Colorectal Cancer</head><p>Colorectal cancer, also known as colon cancer or rectal cancer, is a malignancy that affects the colon or rectum within the digestive system <ref type="bibr" target="#b94">[96]</ref>. Worldwide, it is the third most common cancer, accounting for approximately 10% of all cancer cases, and it is the second leading cause of cancer-related deaths <ref type="bibr" target="#b95">[97]</ref>. It is predominantly found in people over the age of 50, and it initiates as small clumps of cells called polyps that form inside the colon <ref type="bibr" target="#b96">[98]</ref>. Recently, a novel thieno[3,2-c]pyridine compound called "JFY-001," designed to target copper ions specifically, demonstrated significant potential in inhibiting colorectal cancer cell proliferation, inducing cuproptosis, and disrupting cellular metabolic processes <ref type="bibr" target="#b97">[99]</ref>. When combined with a programmed cell death protein (PD-1) inhibitor, it displayed enhanced antitumor effects, all while exhibiting minimal toxicity to normal cells <ref type="bibr" target="#b97">[99]</ref>. Elevated serum copper levels associated with cancer staging and progression in colorectal cancer further underline the significance of targeting copper ions in cancer therapy <ref type="bibr" target="#b98">[100]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2.3.">Prostate Cancer</head><p>Prostate cancer ranks among the most prevalent cancers in men, primarily affecting older individuals, with approximately one in eight men being diagnosed <ref type="bibr" target="#b99">[101]</ref>. It originates in the prostate gland, a crucial part of the male reproductive system positioned beneath the bladder and in front of the rectum <ref type="bibr" target="#b100">[102]</ref>. Early detection significantly increases the chances of successful treatment as the cancer is confined to the prostate gland. Fortunately, most prostate cancers tend to grow slowly and are low-grade, carrying relatively low risks <ref type="bibr" target="#b101">[103]</ref>. However, certain aggressive forms of prostate cancer can rapidly spread throughout the body <ref type="bibr" target="#b101">[103]</ref>. In the progression of prostate cancer, there is an observable increase in serum copper levels <ref type="bibr" target="#b102">[104]</ref>. A recent study introduces a steroid-based compound that effectively inhibits CTR1 and reduces copper intake in prostate cancer cells, leading to suppressed cell proliferation and progression <ref type="bibr" target="#b103">[105]</ref>. This highlights the potential of steroid based CTR1 inhibitors as promising candidates for targeted therapies against cancers dependent on elevated copper levels <ref type="bibr" target="#b103">[105]</ref>. Furthermore, copper ionophores have been shown to be an effective therapeutic potential against prostate cancer in vitro and in transgenic adenocarcinoma of mouse prostate (TRAMP) mice, despite unclear molecular mechanisms <ref type="bibr" target="#b104">[106]</ref>. Copper ionophore treatments, including disulfiram and clioquinol, elicit toxic levels of ROS specifically within TRAMP cells, while exhibiting no such effect on normal mouse prostate epithelial cells <ref type="bibr" target="#b104">[106]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2.4.">Uveal Melanoma</head><p>Uveal melanoma (UM) is the most common primary intraocular, or eye, malignancy as it occurs in about every five people per million each year globally <ref type="bibr" target="#b105">[107]</ref>. There is a lack of effective treatment for UM, and once metastasis occurs, life expectancy can be very poor since most patients of UM succumb to their disease within a year <ref type="bibr" target="#b106">[108]</ref>. In studies, it was found that the Cu + accumulation in the UM cells leads to lipoylated proteins aggregating and targeting Fe-S cluster proteins, which leads to cuproptosis <ref type="bibr" target="#b107">[109]</ref>. Furthermore, it was found that with the treatment of elesclomol, the viability of the UM cell line M619 decreased, and the ability to migrate and the invasiveness of UM cells were also suppressed <ref type="bibr" target="#b107">[109]</ref>. These results yield the conclusion that cuproptosis has a potential therapeutic value for UM patients. Furthermore, recent studies have focused on the relationship between copperrelated genes (CRGs) and the prognosis of UM. Three CRGs were tested: ORAI2, ACADSB, and SLC47A, and it was found that all three of these CRGs are unfavorable for the prognosis of UM <ref type="bibr" target="#b108">[110]</ref>. Greater expression of these CRGs can lead to an unfavorable prognosis for UM. Furthermore, UM is identified with mutations in GNAQ and GNA11 genes, which are also CRGs, and elesclomol is reported to be a GNAQ/GNA11-specific UM inhibitor <ref type="bibr" target="#b108">[110]</ref>. By repurposing elesclomol, it can inhibit the proliferation of cancerous UM cells by targeting GNAQ and GNA11 genes <ref type="bibr" target="#b108">[110]</ref>. This conclusion highlights the key connection between copper, CRGs, and the overall outcome of UM.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.3.">Copper Chelators in Cancer Therapy</head><p>Copper complexes such as copper chelators and copper ionophores have shown promise in cancer targeted therapies <ref type="bibr" target="#b109">[111]</ref>. Copper chelators are capable of binding to copper and reducing its bioavailability, thus inhibiting processes such as angiogenesis, which is necessary for tumor growth and metastasis <ref type="bibr" target="#b110">[112]</ref>. Certain copper chelation strategies have advanced to clinical trials, including tetrathiomolybdate (TTM) and D-penicillamine (D-Pen) <ref type="bibr" target="#b4">[5]</ref>. Moreover, there have been studies where TMM has shown an effect on the reduction in lung, breast, and prostate cancers as well as on squamous cell carcinoma <ref type="bibr" target="#b4">[5]</ref>. However, it is important to note that copper chelators are not adequate by themselves to destroy malignant cells and must be combined with other drugs to accomplish a promising therapeutic approach for cancer <ref type="bibr" target="#b111">[113]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.4.">Copper Ionophores in Cancer Therapy</head><p>Copper ionophore compounds, including elesclomol, chloroquinol, and disulfiram, are known to increase intracellular copper bioavailability <ref type="bibr" target="#b112">[114]</ref>. These compounds release copper within the intracellular environment, triggering various responses. Notably, this leads to an increased production of ROS and restrains proteasome activity in cancer cells, ultimately enabling cell death <ref type="bibr" target="#b4">[5]</ref>. Recent research has demonstrated the efficacy of copper ionophores in reducing tumor growth in models of both prostate and breast cancer <ref type="bibr" target="#b108">[110]</ref>. As these compounds find applications in therapy, studies have revealed that combining copper ionophores with proteasome inhibitors can stimulate a high mitochondrial state in cells, increasing mitochondrial respiration, posing as an interesting area to study for a possible future application towards tumor therapy <ref type="bibr" target="#b11">[13]</ref>. Figure <ref type="figure" target="#fig_12">7</ref> highlights the mechanism of copper ionophores, specifically elesclomol, entering the mitochondria and inducing a hyperactive respiration state. Despite these promising findings, it is important to note that the field of copper metal-binding compounds as cancer therapeutics is still in its early stages of development and requires further exploration. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.5.">Elesclomol: An Anticancer Agent</head><p>Cancer cells exhibit a remarkable ability to evade the tightly regulated pathways of cellular death, a hallmark feature of their malignancy <ref type="bibr" target="#b113">[115]</ref>. This evasion has posed a challenge within cancer therapies as the resistance of cancer cells to programmed cell death </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.5.">Elesclomol: An Anticancer Agent</head><p>Cancer cells exhibit a remarkable ability to evade the tightly regulated pathways of cellular death, a hallmark feature of their malignancy <ref type="bibr" target="#b113">[115]</ref>. This evasion has posed a challenge within cancer therapies as the resistance of cancer cells to programmed cell death pathways diminishes treatment efficacy <ref type="bibr" target="#b114">[116]</ref>. However, cuproptosis presents a potential opportunity for overcoming this resistance and promoting cell death in cancer cells. Among the noteworthy developments, the emergence of the Cu 2+ carrier, elesclomol, has been successful thus far, showing the ability to kill specific drug-resistant cancer cells <ref type="bibr" target="#b52">[54]</ref>. This discovery not only emphasizes the potential of cuproptosis as a therapeutic cancer avenue, but it also highlights the tangible progress being made in identifying agents that can effectively target and eliminate cancer cells selectively without harming normal cells <ref type="bibr" target="#b115">[117]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.6.">Copper Serum Levels and Cancer</head><p>More recently, there has been ongoing research on the connection between copper and cancer <ref type="bibr" target="#b116">[118]</ref>. Studies have found that cancer patients have elevated copper levels in both their serum and cancer tissue in a multitude of cancers such as oral, ovarian, gastric, breast, renal, thyroid, esophageal, lung, gallbladder, liver, pancreatic, and prostate cancers <ref type="bibr" target="#b4">[5]</ref>. In specific cases, such as colorectal and breast cancer, elevated serum copper levels have been associated with cancer staging and progression <ref type="bibr" target="#b117">[119]</ref>. Conversely, decreased serum copper levels have been correlated with colorectal and endometrial cancer <ref type="bibr" target="#b4">[5]</ref>. In addition, it has been found that when the tumor was removed, the Cu serum concentrations returned to the normal threshold as seen in healthy patients <ref type="bibr" target="#b4">[5]</ref>. Furthermore, copper's impact on cancer is not limited to its association with serum and tissue levels. It has been found that tumor cells heavily rely on copper for metabolism, and a decrease in or an abundance of copper can have detrimental effects on tumor cells <ref type="bibr" target="#b118">[120]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.7.">Copper in Wilson Disease</head><p>Wilson disease is a rare genetic disorder that arises from an endogenous accumulation of copper in the body within vital organs, notably the brain, liver, and cornea <ref type="bibr" target="#b119">[121]</ref>. Symptoms are predominantly linked to the affected areas, presenting as liver-related issues such as vomiting, yellowish skin discoloration, and leg swelling, or neurological symptoms like tremors, speech difficulties, personality alterations, and auditory or visual hallucinations <ref type="bibr" target="#b119">[121]</ref>. This condition follows an autosomal recessive pattern, impacting approximately 1 in every 30,000 individuals <ref type="bibr" target="#b119">[121]</ref>. The primary factor contributing to Wilson disease is a mutation in the ATP7B gene, a crucial copper transport protein responsible for biliary copper excretion <ref type="bibr" target="#b120">[122]</ref>. Mutations in this gene result in the abnormal accumulation of copper in both the liver and brain <ref type="bibr" target="#b28">[30]</ref>. Compared to many neurogenetic diseases, Wilson disease responds well to treatment during both its acute and chronic stages <ref type="bibr" target="#b121">[123]</ref>. Treatment is lifelong and patients can anticipate a normal life expectancy. The objective of therapy for Wilson disease is to normalize and reduce the concentration of free copper in serum, accomplished through the administration of copper chelators such as D-Pen and trientine <ref type="bibr" target="#b122">[124]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.8.">Copper in Menkes Disease</head><p>Menkes disease is a lethal X-linked recessive disorder characterized by a deficiency of copper <ref type="bibr" target="#b123">[125]</ref>. Initially documented in 1962, this condition now impacts 1 in every 35,000 live male births <ref type="bibr" target="#b124">[126,</ref><ref type="bibr" target="#b125">127]</ref>. It originates from a mutation in the ATP7A gene, a crucial regulator of copper metabolism in the body <ref type="bibr" target="#b126">[128]</ref>. The gene is responsible for facilitating the efflux of copper from absorptive cells, but its dysfunction results in a deficiency of this essential mineral <ref type="bibr" target="#b127">[129]</ref>. Menkes disease presents itself with various symptoms, including weakened bones, seizures, kinky hair, and slow physical development <ref type="bibr" target="#b127">[129]</ref>. Unfortunately, this rare disease often leads to early childhood mortality. While treatment options exist, such as daily copper injections administrated shortly after birth, there is still difficulty in achieving early diagnosis due to the subtle clinical features and the lack of specific biomarkers <ref type="bibr" target="#b128">[130]</ref>. Currently, a definitive cure for Menkes disease remains elusive. However, early intervention with copper-histidine treatment shows promise in ameliorating some of the neurological symptoms associated with the condition <ref type="bibr" target="#b123">[125]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.">Targets and Biomarkers</head><p>As research on copper ionophores is ongoing, there are yet to be specific biomarkers that have been identified. However, there are proteins that serve as potential biomarkers. These proteins include chaperone proteins (Section 4.1), membrane proteins (Section 4.2), and intracellular proteins (Section 4.3).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.1.">Copper Chaperone Protein Biomarkers</head><p>Copper chaperones are another type of copper transporters. Their role is to ensure the safe handling and delivery of potentially toxic copper ions to a variety of copper proteins that are essential for copper metabolism. There are various copper chaperones, but some essential ones are ATOX1, CCS, COX17, COX11, and SCO1 (Table <ref type="table" target="#tab_3">2</ref>) <ref type="bibr" target="#b129">[131,</ref><ref type="bibr" target="#b130">132]</ref>. First, ATOX1 binds to Cu + and associates with ATP7A and ATP7B, which makes it part of the copper metalation pathway <ref type="bibr" target="#b129">[131]</ref>. Copper chaperone for superoxide dismutase (CCS) is another copper chaperone, and it is responsible for forming heterodimers with copper-zinc superoxide dismutase <ref type="bibr" target="#b131">[133]</ref>. Tests have revealed that CCS protein concentrations are higher in many cells that are found in copper-deficient mammals <ref type="bibr" target="#b130">[132]</ref>. Thus, it can be a potential biomarker for copper level status. COX17 is another chaperone for copper and it is widely believed that most mitochondrial copper is delivered by this protein <ref type="bibr" target="#b130">[132]</ref>. COX17 is 1 of 30 assembly factors necessary for the formation of active cytochrome c oxidase (CCO) and is believed to transfer copper from the cytoplasm into mitochondria <ref type="bibr" target="#b90">[92]</ref>. COX11, like COX17, is another copper chaperone which is also 1 of 30 assembly factors for CCO91. COX1, a subunit of CCO, receives most of its copper from COX11. SCO1 and SCO2 are two more copper chaperones that deliver copper directly to the copper-binding site of COX2 and control the homeostasis of copper within cells <ref type="bibr" target="#b130">[132]</ref>. When copper enters the intestines, specifically the duodenum, the first transporter it interacts with is CTR1 (Table <ref type="table" target="#tab_3">2</ref>) <ref type="bibr" target="#b130">[132]</ref>. It is widely believed that CTR1 is the main protein responsible for the transport of copper across the microvilli layer in the duodenum <ref type="bibr" target="#b130">[132]</ref>. Through the CTR1 protein, copper can enter the bloodstream and cells. CTR2 is another protein that plays a role in copper import and intracellular copper homeostasis. However, the regulation of copper by CTR2 has not been published yet <ref type="bibr" target="#b130">[132]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.2.">Membrane Protein Biomarkers</head><p>Divalent metal transport 1 (DMT1) (Table <ref type="table" target="#tab_3">2</ref>), also known as SLCA112, is a membrane protein that is associated with iron transport; however, it can transport both forms of copper, Cu 2+ and Cu + <ref type="bibr" target="#b132">[134]</ref>. This import of copper occurs under certain conditions, such as a deficiency in CTR1 (Table <ref type="table" target="#tab_3">2</ref>) <ref type="bibr" target="#b113">[115]</ref>. Another membrane-bound protein, amyloid precursor protein (APP) (Table <ref type="table" target="#tab_3">2</ref>), primarily known for its involvement in neurobiology and neurodegenerative disorders could serve as a potential biomarker for copper ionophores and compels further investigation <ref type="bibr" target="#b133">[135]</ref>. Given copper's relevance to neuronal function as well as its association with neurodegenerative diseases, it is important to assess if copper ionophores impact APP expression, processing, or metabolism. With its relation to copper, APP is involved in copper homeostasis, and studies have found that an over expression of APP decreases copper levels in the brain <ref type="bibr" target="#b129">[131]</ref>. Experimental studies using cellular models could shed light on more potential connections between copper ionophores and APP.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.3.">Intracellular Protein Biomarkers</head><p>Intracellular proteins are being explored as potential biomarkers for copper ionophores, revealing insights into the intricate network of copper metabolism within cells. Metallothionein (MT) (Table <ref type="table" target="#tab_3">2</ref>), known for its role in storage and chaperoning, serves as a protein of interest <ref type="bibr" target="#b134">[136]</ref>. MT responds to high copper exposure by enhancing copper entrapment and subsequent loss upon cell shedding in the intestine. Copper triggers MT transcription, but its viability as a biomarker requires further study <ref type="bibr" target="#b135">[137]</ref>. The copper metabolism MURR domain, represented by COMMD1, is crucial for hepatic copper efflux; it is also tightly linked to ATP7B interaction, a copper-transporting protein <ref type="bibr" target="#b136">[138]</ref>. COMMD1 also interacts with the X-linked inhibitor of apoptosis (XIAP), suggesting a greater influence <ref type="bibr" target="#b137">[139]</ref>. XIAP is essential for COMMD1 degradation as it contributes to normal hepatic copper efflux through its interaction with ATP7B <ref type="bibr" target="#b138">[140]</ref>. Excess copper in the liver accelerates XIAP catabolism <ref type="bibr" target="#b129">[131]</ref>. Furthermore, COMMD1 (Table <ref type="table" target="#tab_3">2</ref>) expression with changes in copper levels have yet to be studied; further research could offer insights into its potential as a biomarker in copper ionophores <ref type="bibr" target="#b129">[131]</ref>. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5.">Conclusions and Perspectives</head><p>The study of cuproptosis and its potential implications in cancer therapy paves a promising avenue for further research and clinical applications. As research progresses, several key directions can be pursued. Molecules, proteins, and signaling cascades involved in cuproptosis and cellular defense responses against copper-induced damage, as well as genetic and epigenetic factors that could influence one's susceptibility to this novel form of cell death, could be explored. Additionally, to facilitate the advancement of clinical trials and research, the identification of sensitive copper-dependent biomarkers as well as copper ionophore biomarkers becomes crucial <ref type="bibr" target="#b145">[147]</ref>. Exploring the changes in mRNA expression and or the protein abundance of copper transporters in response to dietary copper intake could provide valuable insight for potential biomarkers <ref type="bibr" target="#b4">[5]</ref>. Moreover, enhancing the selectivity of copper ionophores for cancer cells, as they are currently in the developmental stage for cancer-targeted therapy, holds great potential for improving their clinical efficacy and reducing off-target effects <ref type="bibr" target="#b110">[112]</ref>. However, before any meaningful progression can occur in linking cuproptosis and copper to targeted cancer therapy, the regulatory mechanisms underlying cuproptosis must be determined <ref type="bibr" target="#b4">[5]</ref>. Finally, the correlation between cuproptosis and cancer needs further exploration, emphasizing the significance of clinical trials that focus on targeting copper in cancer therapy <ref type="bibr" target="#b8">[9]</ref>. As the research community aims to understand the intricacies of cuproptosis, its progression holds potential for novel therapeutic strategies that could improve cancer treatment. </p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc>Figure 1. Annual count of cuproptosis-related publications utilizing the PubMED search engine.In 2021, the first cuproptosis-related article was published<ref type="bibr" target="#b10">[11]</ref>, cited 65 times. In 2022, Tsvetkov and colleagues introduced the concept of a distinct form of regulated cell death induced by copper, known as cuproptosis, cited 844 times. The same year saw a notable surge, with 279 publications exploring cuproptosis, followed by a continued increase in 2023 with 580 publications. As of 2024, an additional 40 publications have been dedicated to the study of cuproptosis thus far[12].</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2 .</head><label>2</label><figDesc>Figure 2. Copper-induced cell death milestones [13-18].</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 2 .</head><label>2</label><figDesc>Figure 2. Copper-induced cell death milestones [13-18].</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 3 .</head><label>3</label><figDesc>Figure 3. Reaction step of elesclomol chelated with copper (II) ion [64]. Elesclomol is converted to elesclomol-Copper (II) with the addition of copper (II) ion in the extracellular environment.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Figure 3 .</head><label>3</label><figDesc>Figure 3. Reaction step of elesclomol chelated with copper (II) ion [64]. Elesclomol is converted to elesclomol-Copper (II) with the addition of copper (II) ion in the extracellular environment.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Figure 4 .</head><label>4</label><figDesc>Figure 4. Mechanisms of copper-induced cell death. Elesclomol and CTR1 shuttle Cu 2+ into the mitochondrial matrix, creating an accumulation of copper. FDX1 reduces Cu 2+ to Cu + , resulting in ROS formation. Cu + and ROS block the synthesis of Fe-S clusters. FDX1 also binds to LIAS, promoting the lipoylation of DLAT. Cu + further binds to lipoylated DLAT and induces aggregation. Mitochondrial ROS, loss of Fe-S clusters, and DLAT aggregation all contribute to cuproptosis cell death.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head>Figure 4 .</head><label>4</label><figDesc>Figure 4. Mechanisms of copper-induced cell death. Elesclomol and CTR1 shuttle Cu 2+ into the mitochondrial matrix, creating an accumulation of copper. FDX1 reduces Cu 2+ to Cu + , resulting in ROS formation. Cu + and ROS block the synthesis of Fe-S clusters. FDX1 also binds to LIAS, promoting the lipoylation of DLAT. Cu + further binds to lipoylated DLAT and induces aggregation. Mitochondrial ROS, loss of Fe-S clusters, and DLAT aggregation all contribute to cuproptosis cell death.</figDesc><graphic coords="6,39.35,268.37,518.88,365.29" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_7"><head>Figure 5 .</head><label>5</label><figDesc>Figure 5. Reaction mechanism of disulfiram chelated with copper (II) ion. Disulfiram is split up into diethyldithiocarbamate, which is then turned into Cu (II) diethyldithiocarbamate with the addition of copper (II) ion in the extracellular environment [73].</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_8"><head>Figure 5 .</head><label>5</label><figDesc>Figure 5. Reaction mechanism of disulfiram chelated with copper (II) ion. Disulfiram is split up into diethyldithiocarbamate, which is then turned into Cu (II) diethyldithiocarbamate with the addition of copper (II) ion in the extracellular environment [73].</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_9"><head>Figure 6 .</head><label>6</label><figDesc>Figure 6. Copper-induced cell death via copper chelators and ionophores. Copper chelators enter the mitochondrial matrix to remove excess Cu + from the cell. Chelators deplete intracellular Cu + levels, inducing a state of copper deficiency. In contrast, copper ionophores enter the mitochondrial matrix with Cu 2+ , causing copper accumulation. Both processes of copper deficiency and accumulation lead to copper-induced cell death.</figDesc><graphic coords="8,78.97,293.93,437.40,101.95" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_10"><head>Figure 6 .</head><label>6</label><figDesc>Figure 6. Copper-induced cell death via copper chelators and ionophores. Copper chelators enter the mitochondrial matrix to remove excess Cu + from the cell. Chelators deplete intracellular Cu + levels, inducing a state of copper deficiency. In contrast, copper ionophores enter the mitochondrial matrix with Cu 2+ , causing copper accumulation. Both processes of copper deficiency and accumulation lead to copper-induced cell death.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_11"><head>Cancers 2024 , 23 Figure 7 .</head><label>2024237</label><figDesc>Figure 7. Elesclomol mechanism of action in the mitochondria. Mitochondrial entry of elesclomol carrying Cu 2+ induces lipoylation of key TCA enzymes, KDH and PDH. Elesclomol-Cu(II) enters the mitochondrial matrix and FDX1 reduces Cu 2+ to Cu + . Additionally, FDX1 facilitates LIAS lipoylation activity of TCA proteins. Cu + binding to lipoylated-TCA enzymes results in a gain of function, leading to the mitochondria being in a hyperactive respiration state, thus resulting in an increase in ATP.</figDesc><graphic coords="12,88.54,439.78,418.94,294.54" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_12"><head>Figure 7 .</head><label>7</label><figDesc>Figure 7. Elesclomol mechanism of action in the mitochondria. Mitochondrial entry of elesclomol carrying Cu 2+ induces lipoylation of key TCA enzymes, KDH and PDH. Elesclomol-Cu(II) enters the</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc>Comparison of cell death pathways.</figDesc><table /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1 .</head><label>1</label><figDesc>Comparison of cell death pathways.</figDesc><table><row><cell></cell><cell></cell><cell>Main</cell><cell></cell></row><row><cell>Cell Death Pathway</cell><cell>Induction Mechanisms</cell><cell>Proteins/Genes</cell><cell>Disease Implications</cell></row><row><cell></cell><cell></cell><cell>Involved</cell><cell></cell></row><row><cell>Cuproptosis (discovered in</cell><cell></cell><cell></cell><cell></cell></row><row><cell>2022)</cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 1 . Cont. Cell Death Pathway Induction Mechanisms Main Proteins/Genes Involved Disease Implications</head><label>1</label><figDesc></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell>Neurodegenerative diseases</cell></row><row><cell>Ferroptosis (discovered in 2012)</cell><cell>Iron-dependent lipid peroxidation</cell><cell>GPX4 [32,33] GSH [34] DMT1 [16] Ferritin [35,36] 15-Lox [17]</cell><cell>(e.g., Alzheimer's and Parkinson's) [37]. Cancer (e.g., lung, colorectal, prostate, breast, melanoma, hepatocellular carcinoma, pancreatic, and skin)</cell></row><row><cell></cell><cell></cell><cell></cell><cell>[18,38,39].</cell></row><row><cell></cell><cell></cell><cell>Caspase-3 [40]</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Caspase-6-10 [41]</cell><cell></cell></row><row><cell>Apoptosis (discovered in 1972)</cell><cell>Caspase cascades trigger and regulate programmed cell death</cell><cell>BCL-2 [42,43] Cytochrome C [44] Apaf-1 [45]</cell><cell></cell></row><row><cell></cell><cell></cell><cell>CD95, CD95L [46]</cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 2 .</head><label>2</label><figDesc>Targets and biomarkers of copper ionophores related to cuproptosis.</figDesc><table><row><cell>Name</cell><cell>Type of Protein</cell><cell>Function</cell><cell>Reference</cell></row><row><cell>Antioxidant 1 Copper Chaperone (ATOX1)</cell><cell>Chaperone</cell><cell>Binds to Cu + ; part of copper metalation pathway</cell><cell>[131,132,141]</cell></row><row><cell>Copper Chaperone for Superoxide Dismutase (CCS)</cell><cell>Chaperone</cell><cell>Forms heterodimers with dismutase copper-zinc superoxide</cell><cell>[131,132,142]</cell></row><row><cell>Cytochrome C Oxidase Copper Chaperone (COX17)</cell><cell>Chaperone</cell><cell>Delivers mitochondrial copper</cell><cell>[131,132]</cell></row><row><cell>Cytochrome C Oxidase Copper Chaperone (COX11)</cell><cell>Chaperone</cell><cell>Delivers copper to COX1</cell><cell>[132]</cell></row><row><cell>Synthesis of Cytochrome C Oxidase 1 (SCO1 and SCO2)</cell><cell>Chaperone</cell><cell>Delivers copper to COX2 and homeostasis helps maintain copper</cell><cell>[131,132,143]</cell></row><row><cell>High-Affinity Copper Uptake Protein 1 (CTR1)</cell><cell>Chaperone</cell><cell>Transports copper across the lining of the duodenum</cell><cell>[131,132,144]</cell></row><row><cell>High-Affinity Copper Uptake Protein 2 (CTR2)</cell><cell>Chaperone</cell><cell>Helps in copper import and copper homeostasis</cell><cell>[131,132,145]</cell></row><row><cell>Divalent Metal Transporter 1 (DMT1)</cell><cell>Membrane</cell><cell>Transports Cu 2+ and Cu +</cell><cell>[132]</cell></row><row><cell>Amyloid Precursor Protein (APP)</cell><cell>Membrane</cell><cell>Involved in copper system homeostasis in the nervous</cell><cell>[132]</cell></row><row><cell></cell><cell></cell><cell>Controls high copper levels</cell><cell></cell></row><row><cell>Metallothionein (MT)</cell><cell>Intracellular</cell><cell>through copper entrapment</cell><cell>[132,146]</cell></row><row><cell></cell><cell></cell><cell>and cell shedding</cell><cell></cell></row><row><cell>Copper Metabolism Domain-Containing 1 (COMMD1)</cell><cell>Intracellular</cell><cell>Involved in hepatic copper homeostasis</cell><cell>[132]</cell></row></table></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div><head>Acknowledgments:</head><p>We thank the <rs type="funder">Department of Chemistry</rs> and the <rs type="institution">Department of Biology at the University of Massachusetts (UMASS)</rs>. We also express our gratitude to the <rs type="funder">American Cancer Society</rs> under grant number <rs type="grantNumber">RSG-23-1031557-01-ET</rs>, the <rs type="funder">Lung Cancer Research Foundation</rs>, the <rs type="funder">Manning Foundation/IALS Innovation Award</rs>, and <rs type="funder">Mass Ventures Funds</rs>.</p></div>
			</div>
			<listOrg type="funding">
				<org type="funding" xml:id="_HFxa8FX">
					<idno type="grant-number">RSG-23-1031557-01-ET</idno>
				</org>
			</listOrg>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0" />			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">An Overview of Mesopotamian Bronze Metallurgy during the 3rd Millennium BC</title>
		<author>
			<persName><forename type="first">I</forename><surname>De Ryck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Adriaens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Adams</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.culher.2005.04.002</idno>
	</analytic>
	<monogr>
		<title level="j">J. Cult. Herit</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="261" to="268" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Metallic Copper as an Antimicrobial Surface</title>
		<author>
			<persName><forename type="first">G</forename><surname>Grass</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Rensing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Solioz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Appl. Environ. Microbiol</title>
		<imprint>
			<biblScope unit="volume">77</biblScope>
			<biblScope unit="page" from="1541" to="1547" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Barceloux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Barceloux</surname></persName>
		</author>
		<author>
			<persName><surname>Copper</surname></persName>
		</author>
		<idno type="DOI">10.1081/CLT-100102421</idno>
	</analytic>
	<monogr>
		<title level="j">J. Toxicol. Clin. Toxicol</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="217" to="230" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<monogr>
		<title level="m" type="main">Committee on Copper in Drinking Water. Copper in Drinking Water</title>
		<ptr target="https://www.ncbi.nlm.nih.gov/books/NBK225407/" />
		<imprint>
			<date type="published" when="2023-12-12">12 December 2023</date>
			<publisher>National Academies Press</publisher>
			<pubPlace>Washington (DC</pubPlace>
		</imprint>
		<respStmt>
			<orgName>National Research Council (US)</orgName>
		</respStmt>
	</monogr>
	<note>US); 2000, 2, Physiological Role of Copper. Available online</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Regulatory Roles of Copper Metabolism and Cuproptosis in Human Cancers</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Jin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Dong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ji</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>An</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Luo</surname></persName>
		</author>
		<idno type="DOI">10.3389/fonc.2023.1123420</idno>
	</analytic>
	<monogr>
		<title level="j">Front. Oncol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<date type="published" when="2023">2023. 1123420</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Copper Biochemistry and Molecular Biology</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Linder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hazegh-Azam</surname></persName>
		</author>
		<idno type="DOI">10.1093/ajcn/63.5.797</idno>
	</analytic>
	<monogr>
		<title level="j">Am. J. Clin. Nutr</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="797" to="S811" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Connecting Copper and Cancer: From Transition Metal Signalling to Metalloplasia</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Ge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">I</forename><surname>Bush</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Casini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Cobine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Cross</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Denicola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><forename type="middle">P</forename><surname>Dou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Franz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">M</forename><surname>Gohil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gupta</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41568-021-00417-2</idno>
	</analytic>
	<monogr>
		<title level="j">Nat. Rev. Cancer</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="102" to="113" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Copper: An Essential Metal in Biology</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Festa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Thiele</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cub.2011.09.040</idno>
	</analytic>
	<monogr>
		<title level="j">Curr. Biol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="877" to="R883" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Cuproptosis: Mechanisms and Links with Cancers</title>
		<author>
			<persName><forename type="first">J</forename><surname>Xie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>He</surname></persName>
		</author>
		<idno type="DOI">10.1186/s12943-023-01732-y</idno>
	</analytic>
	<monogr>
		<title level="j">Mol. Cancer</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Role of Cuproptosis in Understanding Diseases</title>
		<author>
			<persName><forename type="first">S</forename><surname>Cao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Jia</surname></persName>
		</author>
		<idno type="DOI">10.1007/s13577-023-00914-6</idno>
	</analytic>
	<monogr>
		<title level="j">Hum. Cell</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="1244" to="1252" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Getting out What You Put</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Cobine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Moore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Leary</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.bbamcr.2020.118867</idno>
	</analytic>
	<monogr>
		<title level="m">Copper in Mitochondria and Its Impacts on Human Disease</title>
		<imprint>
			<date type="published" when="1868">2021. 1868. 118867</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Elesclomol, a Copper-Transporting Therapeutic Agent Targeting Mitochondria: From Discovery to Its Novel Applications</title>
		<author>
			<persName><forename type="first">M</forename><surname>Tarin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Babaie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Eshghi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Matin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S H</forename><surname>Saljooghi</surname></persName>
		</author>
		<idno type="DOI">10.1186/s12967-023-04533-5</idno>
	</analytic>
	<monogr>
		<title level="j">J. Transl. Med</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Elesclomol Induces Copper-Dependent Ferroptosis in Colorectal Cancer Cells via Degradation of ATP7A</title>
		<author>
			<persName><forename type="first">W</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Duan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>Nice</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Huang</surname></persName>
		</author>
		<idno type="DOI">10.1002/1878-0261.13079</idno>
	</analytic>
	<monogr>
		<title level="j">Mol. Oncol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="3527" to="3544" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Cuproptosis: P53-Regulated Metabolic Cell Death?</title>
		<author>
			<persName><forename type="first">C</forename><surname>Xiong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Hao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhou</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41418-023-01125-0</idno>
	</analytic>
	<monogr>
		<title level="j">Cell Death Diff</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="876" to="884" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Temozolomide Drives Ferroptosis via a DMT1-Dependent Pathway in Glioblastoma Cells</title>
		<author>
			<persName><forename type="first">Q</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Peng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Heng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhu</surname></persName>
		</author>
		<idno type="DOI">10.3349/ymj.2021.62.9.843</idno>
	</analytic>
	<monogr>
		<title level="j">Yonsei Med. J</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Resolving the Role of Lipoxygenases in the Initiation and Execution of Ferroptosis</title>
		<author>
			<persName><forename type="first">R</forename><surname>Shah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Shchepinov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Pratt</surname></persName>
		</author>
		<idno type="DOI">10.1021/acscentsci.7b00589</idno>
	</analytic>
	<monogr>
		<title level="j">ACS Cent. Sci</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="387" to="396" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Ferroptosis and Its Potential Role in Lung Cancer: Updated Evidence from Pathogenesis to Therapy</title>
		<author>
			<persName><forename type="first">K</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Jiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zhao</surname></persName>
		</author>
		<idno type="DOI">10.2147/JIR.S347955</idno>
	</analytic>
	<monogr>
		<title level="j">J. Inflamm. Res</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="7079" to="7090" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Apoptosis: A Review of Programmed Cell Death</title>
		<author>
			<persName><forename type="first">S</forename><surname>Elmore</surname></persName>
		</author>
		<idno type="DOI">10.1080/01926230701320337</idno>
	</analytic>
	<monogr>
		<title level="j">Toxicol. Pathol</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="495" to="516" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Ferroptosis Turns 10: Emerging Mechanisms, Physiological Functions, and Therapeutic Applications</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Stockwell</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cell.2022.06.003</idno>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">2022</biblScope>
			<biblScope unit="page" from="2401" to="2421" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Pyroptosis: Host Cell Death and Inflammation</title>
		<author>
			<persName><forename type="first">T</forename><surname>Bergsbaken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Fink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">T</forename><surname>Cookson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Rev. Microbiol</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="99" to="109" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Copper Induces Cell Death by Targeting Lipoylated TCA Cycle Proteins</title>
		<author>
			<persName><forename type="first">P</forename><surname>Tsvetkov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Coy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Petrova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dreishpoon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Verma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Abdusamad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Rossen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Joesch-Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Humeidi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Spangler</surname></persName>
		</author>
		<idno type="DOI">10.1126/science.abf0529</idno>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">375</biblScope>
			<biblScope unit="page" from="1254" to="1261" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">The Mammalian Copper Transporters CTR1 and CTR2 and Their Roles in Development and Disease</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">K Y</forename><surname>Wee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Weinstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">T</forename><surname>Fraser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Assinder</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.biocel.2013.01.018</idno>
	</analytic>
	<monogr>
		<title level="j">Int. J. Biochem. Cell Biol</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="960" to="963" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">ATP7A and ATP7B Copper Transporters Have Distinct Functions in the Regulation of Neuronal Dopamine-Î²-Hydroxylase</title>
		<author>
			<persName><forename type="first">K</forename><surname>Schmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ralle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Schaffer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Jayakanthan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Bari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Muchenditsi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lutsenko</surname></persName>
		</author>
		<idno type="DOI">10.1074/jbc.RA118.004889</idno>
	</analytic>
	<monogr>
		<title level="j">J. Biol. Chem</title>
		<imprint>
			<biblScope unit="volume">293</biblScope>
			<date type="published" when="2018">2018. 20085-20098</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Cuproptosis: Cellular and Molecular Mechanisms Underlying Copper-Induced Cell Death</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Cobine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Brady</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.molcel.2022.05.001</idno>
	</analytic>
	<monogr>
		<title level="j">Molecular Cell</title>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope unit="page" from="1786" to="1787" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Progress in the Research of Cuproptosis and Possible Targets for Cancer Therapy</title>
		<author>
			<persName><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L.-Z</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D.-M</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z.-H</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G.-Y</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wen</surname></persName>
		</author>
		<idno type="DOI">10.5306/wjco.v14.i9.324</idno>
	</analytic>
	<monogr>
		<title level="j">World J. Clin. Oncol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="324" to="334" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Cuproptosis-Related Gene SLC31A1: Prognosis Values and Potential Biological Functions in</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Qi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Yao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Qu</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41598-023-44681-8</idno>
	</analytic>
	<monogr>
		<title level="j">Cancer. Sci. Rep</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<date type="published" when="2023">2023. 17790</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">ATF3/SPI1/SLC31A1 Signaling Promotes Cuproptosis Induced by Advanced Glycosylation End Products in Diabetic Myocardial Injury</title>
		<author>
			<persName><forename type="first">S</forename><surname>Huo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Peng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Peng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Men</surname></persName>
		</author>
		<idno type="DOI">10.3390/ijms24021667</idno>
	</analytic>
	<monogr>
		<title level="j">Int. J. Mol. Sci</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<date type="published" when="1667">2023. 1667</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">A Pan-Cancer Analysis of Copper Homeostasis-Related Gene Lipoyltransferase 1: Its Potential Biological Functions and Prognosis Values</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Peng</surname></persName>
		</author>
		<idno type="DOI">10.3389/fgene.2022.1038174</idno>
	</analytic>
	<monogr>
		<title level="j">Front. Genet</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<date type="published" when="2022">2022. 1038174</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Oncogenic Role of Copper-Induced Cell Death-Associated Protein DLD in Human Cancer: A Pan-Cancer Analysis and Experimental Verification</title>
		<author>
			<persName><forename type="first">H</forename><surname>Qi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Zhu</surname></persName>
		</author>
		<idno type="DOI">10.3892/ol.2023.13800</idno>
	</analytic>
	<monogr>
		<title level="j">Oncol. Lett</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">The Multifaceted Roles of Copper in Cancer: A Trace Metal Element with Dysregulated Metabolism, but Also a Target or a Bullet for Therapy</title>
		<author>
			<persName><forename type="first">P</forename><surname>LeliÃ¨vre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Sancey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J.-L</forename><surname>Coll</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Deniaud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Busser</surname></persName>
		</author>
		<idno type="DOI">10.3390/cancers12123594</idno>
	</analytic>
	<monogr>
		<title level="j">Cancers</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">The Selenoprotein Glutathione Peroxidase 4: From Molecular Mechanisms to Novel Therapeutic Opportunities</title>
		<author>
			<persName><forename type="first">K</forename><surname>Weaver</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Skouta</surname></persName>
		</author>
		<idno type="DOI">10.3390/biomedicines10040891</idno>
	</analytic>
	<monogr>
		<title level="j">Biomedicines</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Global Survey of Cell Death Mechanisms Reveals Metabolic Regulation of Ferroptosis</title>
		<author>
			<persName><forename type="first">K</forename><surname>Shimada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Skouta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kaplan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">S</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hayano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Dixon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Valenzuela</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Wolpaw</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Stockwell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Chem. Biol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="497" to="503" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Lipid Peroxidation and Ferroptosis: The Role of GSH and GPx4. Free Radic</title>
		<author>
			<persName><forename type="first">F</forename><surname>Ursini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maiorino</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biol. Med</title>
		<imprint>
			<biblScope unit="volume">152</biblScope>
			<biblScope unit="page" from="175" to="185" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Ferrostatins Inhibit Oxidative Lipid Damage and Cell Death in Diverse Disease Models</title>
		<author>
			<persName><forename type="first">R</forename><surname>Skouta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Dixon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Dunn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Orman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Shimada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Rosenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Lo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Weinberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Linkermann</surname></persName>
		</author>
		<idno type="DOI">10.1021/ja411006a</idno>
	</analytic>
	<monogr>
		<title level="j">J. Am. Chem. Soc</title>
		<imprint>
			<biblScope unit="volume">136</biblScope>
			<biblScope unit="page" from="4551" to="4556" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Ferritinophagy and Ferroptosis in Cardiovascular Disease: Mechanisms and Potential Applications</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Qin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Qiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Yan</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.biopha.2021.111872</idno>
	</analytic>
	<monogr>
		<title level="j">Biomed. Pharmacother</title>
		<imprint>
			<biblScope unit="volume">141</biblScope>
			<date type="published" when="2021">2021. 111872</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Ferroptosis Mechanisms Involved in Neurodegenerative Diseases</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">O</forename><surname>Reichert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">A</forename><surname>De Freitas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Sampaio-Silva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Rokita-Rosa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D L</forename><surname>Barros</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Levy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Bydlowski</surname></persName>
		</author>
		<idno type="DOI">10.3390/ijms21228765</idno>
	</analytic>
	<monogr>
		<title level="j">Int. J. Mol. Sci</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Unveiling the Therapeutic Potential of Squalene Synthase: Deciphering Its Biochemical Mechanism, Disease Implications, and Intriguing Ties to Ferroptosis</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">F</forename><surname>PicÃ³n</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Skouta</surname></persName>
		</author>
		<idno type="DOI">10.3390/cancers15143731</idno>
	</analytic>
	<monogr>
		<title level="j">Cancers</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Ferroptosis as a Potential Target for Cancer Therapy</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Razak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">H</forename><surname>Ahmad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41419-023-05930-w</idno>
	</analytic>
	<monogr>
		<title level="j">Cell Death Dis</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Emerging Roles of Caspase-3 in Apoptosis</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Porter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">U</forename><surname>JÃ¤nicke</surname></persName>
		</author>
		<idno type="DOI">10.1038/sj.cdd.4400476</idno>
	</analytic>
	<monogr>
		<title level="j">Cell Death Diff</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="99" to="104" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Caspase Functions in Cell Death and Disease</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Mcilwain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Berger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">W</forename><surname>Mak</surname></persName>
		</author>
		<idno type="DOI">10.1101/cshperspect.a008656</idno>
	</analytic>
	<monogr>
		<title level="j">Cold Spring Harb. Perspect. Biol</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">8656</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Apoptosis and Expression of Bcl-2, Bcl-XL, and Bax in Renal Cell Carcinomas</title>
		<author>
			<persName><forename type="first">G</forename><surname>GobÃ©</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rubin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Sawczuk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Buttyan</surname></persName>
		</author>
		<idno type="DOI">10.1081/CNV-120001177</idno>
	</analytic>
	<monogr>
		<title level="j">Cancer Investig</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="324" to="332" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">A Survey of the Anti-Apoptotic Bcl-2 Subfamily Expression in Cancer Types Provides a Platform to Predict the Efficacy of Bcl-2 Antagonists in Cancer Therapy</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Placzek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kitada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Zhai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Reed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pellecchia</surname></persName>
		</author>
		<idno type="DOI">10.1038/cddis.2010.18</idno>
	</analytic>
	<monogr>
		<title level="j">Cell Death Dis</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page">1</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Cytochrome C-Mediated Apoptosis</title>
		<author>
			<persName><forename type="first">X</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.1146/annurev.biochem.73.011303.073706</idno>
	</analytic>
	<monogr>
		<title level="j">Annu. Rev. Biochem</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page" from="87" to="106" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Apaf-1: Regulation and Function in Cell Death</title>
		<author>
			<persName><forename type="first">R</forename><surname>Shakeri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kheirollahi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Davoodi</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.biochi.2017.02.001</idno>
	</analytic>
	<monogr>
		<title level="j">Biochimie</title>
		<imprint>
			<biblScope unit="volume">135</biblScope>
			<biblScope unit="page" from="111" to="125" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<monogr>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Bullani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Wehrli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Viard-Leveugle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Rimoldi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J.-C</forename><surname>Cerottini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J.-H</forename><surname>Saurat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tschopp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>French</surname></persName>
		</author>
		<idno type="DOI">10.1097/00008390-200206000-00010</idno>
		<title level="m">Frequent Downregulation of Fas (CD95) Expression and Function in Melanoma. Melanoma Ress</title>
		<imprint>
			<date type="published" when="2002">2002</date>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="263" to="270" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">A Caspase-Activated DNase That Degrades DNA during Apoptosis, and Its Inhibitor ICAD</title>
		<author>
			<persName><forename type="first">M</forename><surname>Enari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Sakahira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yokoyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Okawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Iwamatsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nagata</surname></persName>
		</author>
		<idno type="DOI">10.1038/34112</idno>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">391</biblScope>
			<biblScope unit="page" from="43" to="50" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Role of Apoptosis in Disease</title>
		<author>
			<persName><forename type="first">B</forename><surname>Favaloro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Allocati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Graziano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Di Ilio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>De Laurenzi</surname></persName>
		</author>
		<idno type="DOI">10.18632/aging.100459</idno>
	</analytic>
	<monogr>
		<title level="j">Aging</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="330" to="349" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Apoptosis in Autoimmune Diseases</title>
		<author>
			<persName><forename type="first">K</forename><surname>Eguchi</surname></persName>
		</author>
		<idno type="DOI">10.2169/internalmedicine.40.275</idno>
	</analytic>
	<monogr>
		<title level="j">Inter. Med</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="275" to="284" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Molecular Mechanisms and Functions of Pyroptosis, Inflammatory Caspases and Inflammasomes in Infectious Diseases</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Man</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Karki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T.-D</forename><surname>Kanneganti</surname></persName>
		</author>
		<idno type="DOI">10.1111/imr.12534</idno>
	</analytic>
	<monogr>
		<title level="j">Immunol. Rev</title>
		<imprint>
			<biblScope unit="volume">277</biblScope>
			<biblScope unit="page" from="61" to="75" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<author>
			<persName><forename type="first">Y</forename><surname>Pan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Cai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Yin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Jia</surname></persName>
		</author>
		<idno type="DOI">10.3389/fimmu.2022.991044</idno>
	</analytic>
	<monogr>
		<title level="m">Pyroptosis in Development</title>
		<imprint>
			<date type="published" when="2022">2022. 991044</date>
			<biblScope unit="volume">13</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">Z</forename><surname>Dai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W.-B</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D-Mediated</forename><surname>Gasdermin</surname></persName>
		</author>
		<author>
			<persName><surname>Pyroptosis</surname></persName>
		</author>
		<idno type="DOI">10.3389/fimmu.2023.1178662</idno>
	</analytic>
	<monogr>
		<title level="j">Diseases, and Inhibitors. Front. Imunol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<date type="published" when="2023">2023. 1178662</date>
			<publisher>Mechanisms</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Inflammasome Activation-Mediated Pyroptosis Aggravates Myocardial Ischemia/Reperfusion Injury in Diabetic Rats</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Qiu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Meng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Leng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z.-Y</forename><surname>Xia</surname></persName>
		</author>
		<idno type="DOI">10.1155/2017/9743280</idno>
	</analytic>
	<monogr>
		<title level="j">Oxid. Med. Cell. Longev</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<date type="published" when="2017">2017. 2017</date>
		</imprint>
	</monogr>
	<note>NLRP</note>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">The Role and Mechanism of Pyroptosis and Potential Therapeutic Targets in Sepsis: A Review</title>
		<author>
			<persName><forename type="first">X</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Gong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Chen</surname></persName>
		</author>
		<idno type="DOI">10.3389/fimmu.2021.711939</idno>
	</analytic>
	<monogr>
		<title level="j">Front. Immunol. 2021</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">711939</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Gasdermin-E-Mediated Pyroptosis Participates in the Pathogenesis of Crohn&apos;s Disease by Promoting Intestinal Inflammation</title>
		<author>
			<persName><forename type="first">T</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Zhi</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.celrep.2021.109265</idno>
	</analytic>
	<monogr>
		<title level="j">Cell Rep</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<date type="published" when="2021">2021. 10926</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Pyroptosis and Its Role in Autoimmune Disease: A Potential Therapeutic Target</title>
		<author>
			<persName><forename type="first">R</forename><surname>You</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Zeng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Xiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Xiao</surname></persName>
		</author>
		<idno type="DOI">10.3389/fimmu.2022.841732</idno>
	</analytic>
	<monogr>
		<title level="j">Front. Immunol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<date type="published" when="2022">2022. 841732</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">What Role Does Pyroptosis Play in Microbial Infection?</title>
		<author>
			<persName><forename type="first">X</forename><surname>Xia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hu</surname></persName>
		</author>
		<idno type="DOI">10.1002/jcp.27909</idno>
	</analytic>
	<monogr>
		<title level="j">J. Cell. Physiol</title>
		<imprint>
			<biblScope unit="volume">234</biblScope>
			<biblScope unit="page" from="7885" to="7892" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Pyroptosis: A New Paradigm of Cell Death for Fighting against</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Tan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Zeng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Xiong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Xiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Yi</surname></persName>
		</author>
		<idno type="DOI">10.1186/s13046-021-01959-x</idno>
	</analytic>
	<monogr>
		<title level="j">Cancer. J. Exp. Clin. Cancer Res</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Copper and Zinc Levels in Normal and Malignant Tissues</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Margalioth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Schenker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Chevion</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="868" to="872" />
			<date type="published" when="1983">1983</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Copper Binding Agents Acting as Copper Ionophores Lead to Caspase Inhibition and Paraptotic Cell Death in Human Cancer Cells</title>
		<author>
			<persName><forename type="first">S</forename><surname>Tardito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Bassanetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bignardi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Elviri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tegoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mucchino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Bussolati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Franchi-Gazzola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>MarchiÃ²</surname></persName>
		</author>
		<idno type="DOI">10.1021/ja109413c</idno>
	</analytic>
	<monogr>
		<title level="j">J. Am. Chem. Soc</title>
		<imprint>
			<biblScope unit="volume">133</biblScope>
			<biblScope unit="page" from="6235" to="6242" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Zhou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cuproptosis: A New Form of Programmed Cell Death. Cell. Mol. Immunol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="867" to="868" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Copper Coordination Compounds as Biologically Active Agents</title>
		<author>
			<persName><forename type="first">O</forename><surname>Krasnovskaya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Naumov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Guk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Gorelkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Erofeev</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Beloglazkina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Majouga</surname></persName>
		</author>
		<idno type="DOI">10.3390/ijms21113965</idno>
	</analytic>
	<monogr>
		<title level="j">Int. J. Mol. Sci</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">The Cytotoxicity of the Anticancer Drug Elesclomol Is due to Oxidative Stress Indirectly Mediated through Its Complex with Cu(II)</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">B</forename><surname>Hasinoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Yadav</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wu</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jinorgbio.2014.04.004</idno>
	</analytic>
	<monogr>
		<title level="j">J. Inorg. Biochem</title>
		<imprint>
			<biblScope unit="volume">137</biblScope>
			<biblScope unit="page" from="22" to="30" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Repurposing Elesclomol, an Investigational Drug for the Treatment of Copper Metabolism Disorders</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">M</forename><surname>Gohil</surname></persName>
		</author>
		<idno type="DOI">10.1080/13543784.2021.1840550</idno>
	</analytic>
	<monogr>
		<title level="j">Expert Opin. Investig. Drugs</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="1" to="4" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Elesclomol: A Copper Ionophore Targeting Mitochondrial Metabolism for Cancer Therapy</title>
		<author>
			<persName><forename type="first">P</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ding</surname></persName>
		</author>
		<idno type="DOI">10.1186/s13046-022-02485-0</idno>
	</analytic>
	<monogr>
		<title level="j">J. Exp. Clin. Cancer Res</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">Copper-Binding Small Molecule Induces Oxidative Stress and Cell-Cycle Arrest in Glioblastoma-Patient-Derived Cells</title>
		<author>
			<persName><forename type="first">K</forename><surname>Shimada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Reznik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Stokes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Krishnamoorthy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Bos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Quartararo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">C</forename><surname>Pagano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Carpizo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Decarvalho</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.chembiol.2018.02.010</idno>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="585" to="594" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note>e7. [CrossRef]</note>
</biblStruct>

<biblStruct xml:id="b65">
	<monogr>
		<title level="m" type="main">FDX1 Regulates Cellular Protein Lipoylation through Direct Binding to LIAS</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Dreishpoon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">R</forename><surname>Bick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Petrova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Warui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cameron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Booker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Kanarek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">R</forename><surname>Golub</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Tsvetkov</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jbc.2023.105046</idno>
		<imprint>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">Cuproptosis: Lipoylated TCA Cycle Proteins-Mediated Novel Cell Death Pathway</title>
		<author>
			<persName><forename type="first">S.-R</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L.-L</forename><surname>Bu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Cai</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41392-022-01014-x</idno>
	</analytic>
	<monogr>
		<title level="j">Signal Transduct. Target Ther</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">158</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Read</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E T</forename><surname>Bentley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Archer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Dunham-Snary</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.redox.2021.102164</idno>
	</analytic>
	<monogr>
		<title level="m">Mitochondrial Iron-Sulfur Clusters: Structure, Function, and an Emerging Role in Vascular Biology</title>
		<imprint>
			<date type="published" when="2021">2021. 102164</date>
			<biblScope unit="volume">47</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">Copper Homeostasis and Cuproptosis in Atherosclerosis: Metabolism, Mechanisms and Potential Therapeutic Strategies</title>
		<author>
			<persName><forename type="first">S</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wu</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41420-023-01796-1</idno>
	</analytic>
	<monogr>
		<title level="j">Cell Death Discov</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<date type="published" when="2024">2024</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">The Tumor Microenvironment Innately Modulates Cancer Progression</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Hinshaw</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Shevde</surname></persName>
		</author>
		<idno type="DOI">10.1158/0008-5472.CAN-18-3962</idno>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">79</biblScope>
			<biblScope unit="page" from="4557" to="4566" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main">Disulfiram Facilitates Intracellular Cu Uptake and Induces Apoptosis in Human Melanoma Cells</title>
		<author>
			<persName><forename type="first">D</forename><surname>Cen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">F</forename><surname>Brayton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Shahandeh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Meyskens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Farmer</surname></persName>
		</author>
		<idno type="DOI">10.1021/jm049568z</idno>
	</analytic>
	<monogr>
		<title level="j">J. Med. Chem</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="6914" to="6920" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">Development of Injectable PEGylated Liposome Encapsulating Disulfiram for Colorectal Cancer Treatment</title>
		<author>
			<persName><forename type="first">M</forename><surname>Najlah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Said Suliman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Tolaymat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kurusamy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Kannappan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M A</forename><surname>Elhissi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.3390/pharmaceutics11110610</idno>
	</analytic>
	<monogr>
		<title level="j">Pharmaceutics</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">610</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main">The Cell: A Molecular Approach</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Cooper</surname></persName>
		</author>
		<ptr target="https://www.ncbi.nlm.nih.gov/books/NBK9896/" />
	</analytic>
	<monogr>
		<title level="m">Sinauer Associates: Sunderland, MA, USA, 2000. Available online</title>
		<editor>
			<persName><surname>Mitochondria</surname></persName>
		</editor>
		<imprint>
			<date type="published" when="2023-10-17">17 October 2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Ruiz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Libedinsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Elorza</surname></persName>
		</author>
		<idno type="DOI">10.3389/fmolb.2021.711227</idno>
	</analytic>
	<monogr>
		<title level="j">Role of Copper on Mitochondrial Function and Metabolism. Front. Mol. Biosci</title>
		<imprint>
			<date type="published" when="2021">2021, 8, 711227</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main">Regulation and Function of the Mammalian Tricarboxylic Acid Cycle</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">K</forename><surname>Arnold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">W</forename><surname>Finley</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jbc.2022.102838</idno>
	</analytic>
	<monogr>
		<title level="j">J. Biol. Chem</title>
		<imprint>
			<biblScope unit="volume">299</biblScope>
			<date type="published" when="2022">2022. 102838</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">B</forename><surname>Alberts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lewis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Raff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Roberts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Walter</surname></persName>
		</author>
		<ptr target="https://www.ncbi.nlm.nih.gov/books/NBK26894/" />
	</analytic>
	<monogr>
		<title level="j">The Mitochondrion. Nih.gov</title>
		<imprint>
			<date type="published" when="2002-09-05">2002. 5 September 2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main">Circadian Rhythms in Mitochondrial Respiration</title>
		<author>
			<persName><forename type="first">P</forename><surname>De Goede</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wefers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>Brombacher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Schrauwen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kalsbeek</surname></persName>
		</author>
		<idno type="DOI">10.1530/JME-17-0196</idno>
		<idno>115-R130</idno>
	</analytic>
	<monogr>
		<title level="j">J. Mol. Endocrinol</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main">Lipoic Acid Synthesis and Attachment in Yeast Mitochondria</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Schonauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Kastaniotis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">A S</forename><surname>Kursu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Hiltunen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Dieckmann</surname></persName>
		</author>
		<idno type="DOI">10.1074/jbc.M109.015594</idno>
	</analytic>
	<monogr>
		<title level="j">J. Biol. Chem</title>
		<imprint>
			<biblScope unit="volume">284</biblScope>
			<biblScope unit="page" from="23234" to="23242" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main">Protein Lipoylation: An Evolutionarily Conserved Metabolic Regulator of Health and Disease</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Rowland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">K</forename><surname>Snowden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Cristea</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cbpa.2017.11.003</idno>
	</analytic>
	<monogr>
		<title level="j">Curr. Opin. Chem. Biol</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="76" to="85" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main">TCA Cycle Rewiring as Emerging Metabolic Signature of Hepatocellular Carcinoma</title>
		<author>
			<persName><forename type="first">S</forename><surname>Todisco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Convertini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Iacobazzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Infantino</surname></persName>
		</author>
		<idno type="DOI">10.3390/cancers12010068</idno>
	</analytic>
	<monogr>
		<title level="j">Cancers</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">68</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b80">
	<analytic>
		<title level="a" type="main">Recent Advances in Cancer Therapeutic Copper-Based Nanomaterials for Antitumor Therapy</title>
		<author>
			<persName><forename type="first">R</forename><surname>Aishajiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Yu</surname></persName>
		</author>
		<idno type="DOI">10.3390/molecules28052303</idno>
	</analytic>
	<monogr>
		<title level="j">Molecules</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page">2303</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b81">
	<analytic>
		<title level="a" type="main">Copper and Copper-Based Nanoparticles in Medicine-Perspectives and Challenges</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>WoÅºniak-Budych</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Staszak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Staszak</surname></persName>
		</author>
		<idno type="DOI">10.3390/molecules28186687</idno>
	</analytic>
	<monogr>
		<title level="j">Molecules</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b82">
	<analytic>
		<title level="a" type="main">Recent Advances on Black Phosphorus for Biomedicine and Biosensing</title>
		<author>
			<persName><forename type="first">X</forename><surname>Ge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Xia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Guo</surname></persName>
		</author>
		<idno type="DOI">10.1002/adfm.201900318</idno>
	</analytic>
	<monogr>
		<title level="j">Adv. Funct. Mater</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<date type="published" when="2019">2019. 1900318</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b83">
	<analytic>
		<title level="a" type="main">Type-I AIE Photosensitizer Loaded Biomimetic System Boosting Cuproptosis to Inhibit Breast Cancer Metastasis and Rechallenge</title>
		<author>
			<persName><forename type="first">S</forename><surname>Ning</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lyu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W Y</forename><surname>Lam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">Z</forename><surname>Tang</surname></persName>
		</author>
		<idno type="DOI">10.1021/acsnano.3c00326</idno>
	</analytic>
	<monogr>
		<title level="j">ACS Nano</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="10206" to="10217" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b84">
	<analytic>
		<title level="a" type="main">Copper-Doped Carbon Dots for Optical Bioimaging and Photodynamic Therapy</title>
		<author>
			<persName><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Primo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Tedesco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Bi</surname></persName>
		</author>
		<idno type="DOI">10.1021/acs.inorgchem.9b02283</idno>
	</analytic>
	<monogr>
		<title level="j">Inorg. Chem</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="13394" to="13402" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b85">
	<analytic>
		<title level="a" type="main">An Enzyme-Engineered Nonporous Copper(I) Coordination Polymer Nanoplatform for Cuproptosis-Based Synergistic Cancer Therapy</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zeng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Xu</surname></persName>
		</author>
		<idno type="DOI">10.1002/adma.202204733</idno>
	</analytic>
	<monogr>
		<title level="j">Adv. Mater</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<date type="published" when="2022">2022. 2204733</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b86">
	<monogr>
		<title level="m" type="main">Lung Cancer Overview|Lung Cancer Research &amp; Statistics</title>
		<author>
			<persName><surname>Acs</surname></persName>
		</author>
		<ptr target="https://www.cancer.org/cancer/lung-cancer/about/" />
		<imprint>
			<date type="published" when="2023-11-22">22 November 2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b87">
	<analytic>
		<title level="a" type="main">Non-Small Cell Lung Cancer</title>
		<author>
			<persName><surname>Ysm</surname></persName>
		</author>
		<ptr target="https://www.yalemedicine.org/conditions/non-small-cell-lung-cancer" />
	</analytic>
	<monogr>
		<title level="m">#:~:text=What%20is%20non-small%20cell</title>
		<imprint>
			<date type="published" when="2022-11-22">2022. 22 November 2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b88">
	<monogr>
		<title level="m" type="main">Non-Small Cell Lung Cancer Treatment</title>
		<author>
			<persName><surname>Nci</surname></persName>
		</author>
		<ptr target="https://www.cancer.gov/types/lung/patient/non-small-cell-lung-treatment-pdq" />
		<imprint>
			<date type="published" when="2019-11-22">2019. 22 November 2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b89">
	<analytic>
		<title level="a" type="main">Targeting Copper Metabolism: A Promising Strategy for Cancer Treatment</title>
		<author>
			<persName><forename type="first">R</forename><surname>Kong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Sun</surname></persName>
		</author>
		<idno type="DOI">10.3389/fphar.2023.1203447</idno>
	</analytic>
	<monogr>
		<title level="j">Front. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<date type="published" when="2023">2023. 1203447</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b90">
	<analytic>
		<title level="a" type="main">Copper in Cancer: From Limiting Nutrient to Therapeutic Target</title>
		<author>
			<persName><forename type="first">X</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Yan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Miao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Ha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Mi</surname></persName>
		</author>
		<idno type="DOI">10.3389/fonc.2023.1209156</idno>
	</analytic>
	<monogr>
		<title level="j">Front. Oncol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<date type="published" when="2023">2023. 1209156</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b91">
	<analytic>
		<title level="a" type="main">A Phase IIb Trial Assessing the Addition of Disulfiram to Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer</title>
		<author>
			<persName><forename type="first">H</forename><surname>Nechushtan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Hamamreh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nidal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gotfried</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Baron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">I</forename><surname>Shalev</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Nisman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Peretz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Peylan-Ramu</surname></persName>
		</author>
		<idno type="DOI">10.1634/theoncologist.2014-0424</idno>
	</analytic>
	<monogr>
		<title level="j">Oncologist</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="366" to="367" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b92">
	<analytic>
		<title level="a" type="main">Inhibitory Effect of Disulfiram/Copper Complex on Non-Small Cell Lung Cancer Cells</title>
		<author>
			<persName><forename type="first">L</forename><surname>Duan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Cai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Jin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Huang</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.bbrc.2014.03.047</idno>
	</analytic>
	<monogr>
		<title level="j">Biochem. Biophys. Res. Commun</title>
		<imprint>
			<biblScope unit="volume">446</biblScope>
			<biblScope unit="page" from="1010" to="1016" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b93">
	<analytic>
		<title level="a" type="main">Targeting ALDH1A1 by Disulfiram/Copper Complex Inhibits Non-Small Cell Lung Cancer Recurrence Driven by ALDH-Positive Cancer Stem Cells</title>
		<author>
			<persName><forename type="first">X</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Cui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Yuan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Cao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhang</surname></persName>
		</author>
		<idno type="DOI">10.18632/oncotarget.11305</idno>
	</analytic>
	<monogr>
		<title level="j">Oncotarget</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="58516" to="58530" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b94">
	<monogr>
		<author>
			<persName><surname>Acs</surname></persName>
		</author>
		<author>
			<persName><surname>What</surname></persName>
		</author>
		<ptr target="https://www.cancer.org/cancer/types/colon-rectal-cancer/about/what-is-colorectal-cancer.html" />
		<title level="m">Is Colorectal Cancer?|How Does Colorectal Cancer Start? Available online</title>
		<imprint>
			<date type="published" when="2023-11-23">23 November 2023</date>
		</imprint>
	</monogr>
	<note>#:~:text=Most%20colorectal%20cancers%20start%20as</note>
</biblStruct>

<biblStruct xml:id="b95">
	<monogr>
		<author>
			<orgName type="collaboration">WHO. www.who.int. Colorectal Cancer</orgName>
		</author>
		<ptr target="https://www.who.int/news-room/fact-sheets/detail/colorectal-cancer#" />
		<title level="m">:~:text=Key%20facts</title>
		<imprint>
			<date type="published" when="2023-11-23">23 November 2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b96">
	<analytic>
		<title level="a" type="main">Colon Cancer-Symptoms and Causes. Mayo Clinic</title>
		<ptr target="https://www.mayoclinic.org/diseases-conditions/colon-cancer/symptoms-causes/syc-20353669" />
	</analytic>
	<monogr>
		<title level="j">Mayo Clinic</title>
		<imprint>
			<date type="published" when="2022-11-23">2022. 23 November 2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b97">
	<analytic>
		<title level="a" type="main">A Novel Copper Chelator for the Suppression of Colorectal Cancer</title>
		<author>
			<persName><forename type="first">X</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Jia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Xun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Liu</surname></persName>
		</author>
		<idno type="DOI">10.1002/ddr.22034</idno>
	</analytic>
	<monogr>
		<title level="j">Drug Dev. Res</title>
		<imprint>
			<biblScope unit="volume">84</biblScope>
			<biblScope unit="page" from="312" to="325" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b98">
	<analytic>
		<title level="a" type="main">Blood Copper Levels and the Occurrence of Colorectal Cancer in Poland</title>
		<author>
			<persName><forename type="first">P</forename><surname>Baszuk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Marciniak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Derkacz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Jakubowska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Cybulski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gronwald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>DÄbniak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Huzarski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>BiaÅkowska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pietrzak</surname></persName>
		</author>
		<idno type="DOI">10.3390/biomedicines9111628</idno>
	</analytic>
	<monogr>
		<title level="j">Biomedicines</title>
		<imprint>
			<biblScope unit="volume">2021</biblScope>
			<date type="published" when="1628">1628</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b99">
	<analytic>
		<title level="a" type="main">Key Statistics for Prostate Cancer</title>
		<author>
			<persName><surname>Acs</surname></persName>
		</author>
		<ptr target="https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html" />
	</analytic>
	<monogr>
		<title level="m">#:~:text=The%20American%20Cancer%20Society</title>
		<imprint>
			<date type="published" when="2023-11-23">23 November 2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b100">
	<analytic>
		<title level="a" type="main">American Cancer Fund</title>
		<author>
			<persName><surname>Acf</surname></persName>
		</author>
		<ptr target="https://www.americancancerfund.org/cancer-types/prostate-cancer/" />
	</analytic>
	<monogr>
		<title level="m">?gclid=EAIaIQobChMI8qTksrWv_gIV_A-zAB0zoADOEAAYAiAAEgIlQfD_BwE</title>
		<imprint>
			<date type="published" when="2023-11-23">23 November 2023</date>
		</imprint>
	</monogr>
	<note>Prostate Cancer</note>
</biblStruct>

<biblStruct xml:id="b101">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">W</forename><surname>Leslie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Soon-Sutton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Sajjad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>Siref</surname></persName>
		</author>
		<ptr target="https://www.ncbi.nlm.nih.gov/books/NBK470550/" />
	</analytic>
	<monogr>
		<title level="j">Prostate Cancer. Nih.gov. StatPearls. Available online</title>
		<imprint>
			<date type="published" when="2023-11-23">23 November 2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b102">
	<analytic>
		<title level="a" type="main">Copper Signaling Axis as a Target for Prostate Cancer Therapeutics</title>
		<author>
			<persName><forename type="first">R</forename><surname>Safi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">R</forename><surname>Nelson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Chitneni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Franz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>George</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Zalutsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Mcdonnell</surname></persName>
		</author>
		<idno type="DOI">10.1158/0008-5472.CAN-13-3527</idno>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">74</biblScope>
			<biblScope unit="page" from="5819" to="5831" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b103">
	<analytic>
		<title level="a" type="main">Reduction in Copper Uptake and Inhibition of Prostate Cancer Cell Proliferation by Novel Steroid-Based Compounds</title>
		<author>
			<persName><forename type="first">F</forename><surname>Xie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Peng</surname></persName>
		</author>
		<idno type="DOI">10.21873/anticanres.15414</idno>
	</analytic>
	<monogr>
		<title level="j">Anticancer Res</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="5953" to="5958" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b104">
	<analytic>
		<title level="a" type="main">Copper as a Target for Prostate Cancer Therapeutics: Copper-Ionophore Pharmacology and Altering Systemic Copper Distribution</title>
		<author>
			<persName><forename type="first">D</forename><surname>Denoyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">B</forename><surname>Pearson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Clatworthy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">M</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Francis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Llanos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Volitakis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">A</forename><surname>Phillips</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Meggyesy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Masaldan</surname></persName>
		</author>
		<idno type="DOI">10.18632/oncotarget.9245</idno>
	</analytic>
	<monogr>
		<title level="j">Oncotarget</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="37064" to="37080" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b105">
	<analytic>
		<title level="a" type="main">A Newly Established Cuproptosis-Related Gene Signature for Predicting Prognosis and Immune Infiltration in Uveal Melanoma</title>
		<author>
			<persName><forename type="first">W</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Fang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Lai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Lan</surname></persName>
		</author>
		<idno type="DOI">10.3390/ijms241411358</idno>
	</analytic>
	<monogr>
		<title level="j">Int. J. Mol. Sci</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<date type="published" when="2023">2023. 11358</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b106">
	<analytic>
		<title level="a" type="main">Treatment of Uveal Melanoma: Where Are We Now?</title>
		<author>
			<persName><forename type="first">J</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename><surname>Manson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">P</forename><surname>Marr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Carvajal</surname></persName>
		</author>
		<idno type="DOI">10.1177/1758834018757175</idno>
	</analytic>
	<monogr>
		<title level="j">Ther. Adv. Med. Oncol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<date type="published" when="2018">2018. 175883401875717</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b107">
	<analytic>
		<title level="a" type="main">Identification of a Prognostic Model Using Cuproptosis-Related Genes in Uveal Melanoma</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.3389/fcell.2022.973073</idno>
	</analytic>
	<monogr>
		<title level="j">Front. cell dev. biol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">973073</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b108">
	<analytic>
		<title level="a" type="main">Copper Ionophore Elesclomol Selectively Targets GNAQ/11-Mutant Uveal Melanoma</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Jager</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Jia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41388-022-02364-0</idno>
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="3539" to="3553" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b109">
	<analytic>
		<title level="a" type="main">Selective Targeting of Cancer Cells by Copper Ionophores: An Overview</title>
		<author>
			<persName><forename type="first">V</forename><surname>Oliveri</surname></persName>
		</author>
		<idno type="DOI">10.3389/fmolb.2022.841814</idno>
	</analytic>
	<monogr>
		<title level="j">Front. Mol. Biosci</title>
		<imprint>
			<biblScope unit="volume">2022</biblScope>
			<date>841814</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b110">
	<analytic>
		<title level="a" type="main">Turning Tumor-Promoting Copper into an Anti-Cancer Weapon via High-Throughput Chemistry</title>
		<author>
			<persName><forename type="first">F</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Jiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Qi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Frezza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><forename type="middle">P</forename><surname>Dou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Yan</surname></persName>
		</author>
		<idno type="DOI">10.2174/092986710791859315</idno>
	</analytic>
	<monogr>
		<title level="j">Curr. Med. Chem</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="2685" to="2698" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b111">
	<analytic>
		<title level="a" type="main">Mechanisms for Copper Acquisition, Distribution and Regulation</title>
		<author>
			<persName><forename type="first">B.-E</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Nevitt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Thiele</surname></persName>
		</author>
		<idno type="DOI">10.1038/nchembio.72</idno>
	</analytic>
	<monogr>
		<title level="j">Nat. Chem. Biol</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="176" to="185" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b112">
	<analytic>
		<title level="a" type="main">Relationship between Copper and Immunity: The Potential Role of Copper in Tumor Immunity</title>
		<author>
			<persName><forename type="first">F</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Peng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Ju</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ju</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ouyang</surname></persName>
		</author>
		<idno type="DOI">10.3389/fonc.2022.1019153</idno>
	</analytic>
	<monogr>
		<title level="j">Front. Oncol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<date type="published" when="2022">2022. 1019153</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b113">
	<analytic>
		<title level="a" type="main">Cancer Metabolism and the Evasion of Apoptotic Cell Death</title>
		<author>
			<persName><forename type="first">A</forename><surname>Sharma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Boise</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Shanmugam</surname></persName>
		</author>
		<idno type="DOI">10.3390/cancers11081144</idno>
	</analytic>
	<monogr>
		<title level="j">Cancers</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<date type="published" when="1144">2019. 1144</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b114">
	<analytic>
		<title level="a" type="main">Current Evidence and Therapeutic Implication of PANoptosis in Cancer</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K W</forename><surname>Ocansey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Qian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Cai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ocansey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Amoah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y.-C</forename><surname>Qian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Mao</surname></persName>
		</author>
		<idno type="DOI">10.7150/thno.91814</idno>
	</analytic>
	<monogr>
		<title level="j">Theranostics</title>
		<imprint>
			<biblScope unit="volume">2024</biblScope>
			<biblScope unit="page" from="640" to="661" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b115">
	<monogr>
		<title level="m" type="main">Cuproptosis: A Novel Therapeutic Target for Overcoming Cancer Drug Resistance. Drug Resist</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Fleishman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.drup.2023.101018</idno>
		<imprint/>
	</monogr>
	<note>Update. 2024, 72, 101018. [CrossRef</note>
</biblStruct>

<biblStruct xml:id="b116">
	<analytic>
		<title level="a" type="main">Copper Metabolism as a Unique Vulnerability in Cancer</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">C</forename><surname>Shanbhag</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Gudekar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Jasmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Papageorgiou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Petris</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.bbamcr.2020.118893</idno>
	</analytic>
	<monogr>
		<title level="j">Biochim. Biophys. Acta</title>
		<imprint>
			<date type="published" when="1868">2021. 1868. 118893</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b117">
	<analytic>
		<title level="a" type="main">Serum Essential Elements and Survival after Cancer Diagnosis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Lubi Åski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Lener</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Marciniak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pietrzak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Derkacz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Cybulski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gronwald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>DÄbniak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Jakubowska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Huzarski</surname></persName>
		</author>
		<idno type="DOI">10.3390/nu15112611</idno>
	</analytic>
	<monogr>
		<title level="j">Nutr. J</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<date type="published" when="2023">2023. 2611</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b118">
	<analytic>
		<title level="a" type="main">Copper in Cancer: From Pathogenesis to Therapy</title>
		<author>
			<persName><forename type="first">D</forename><surname>Guan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Chen</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.biopha.2023.114791</idno>
	</analytic>
	<monogr>
		<title level="j">Biomed. Pharmacother</title>
		<imprint>
			<biblScope unit="volume">163</biblScope>
			<date type="published" when="2023">2023. 114791</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b119">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Chaudhry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Anilkumar</surname></persName>
		</author>
		<author>
			<persName><surname>Wilson Disease</surname></persName>
		</author>
		<ptr target="https://www.ncbi.nlm.nih.gov/books/NBK441990/" />
	</analytic>
	<monogr>
		<title level="j">Nih.gov. StatPearls. Available online</title>
		<imprint>
			<date type="published" when="2023-11-27">27 November 2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b120">
	<analytic>
		<title level="a" type="main">The Genetics of Wilson Disease. Wilson Disease</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">J</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Hahn</surname></persName>
		</author>
		<idno type="DOI">10.1016/b978-0-444-63625-6.00003-3</idno>
	</analytic>
	<monogr>
		<title level="j">Handb. Clin. Neurol</title>
		<imprint>
			<biblScope unit="volume">142</biblScope>
			<biblScope unit="page" from="19" to="34" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b121">
	<analytic>
		<title level="a" type="main">Wilson&apos;s Disease: A Master of Disguise</title>
		<author>
			<persName><forename type="first">P</forename><surname>Hedera</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.parkreldis.2019.02.016</idno>
	</analytic>
	<monogr>
		<title level="j">Parkinsonism Relat. Disord</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="140" to="145" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b122">
	<analytic>
		<title level="a" type="main">Therapeutic Strategies in Wilson Disease: Pathophysiology and Mode of Action</title>
		<author>
			<persName><forename type="first">W</forename><surname>Stremmel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Weiskirchen</surname></persName>
		</author>
		<idno type="DOI">10.21037/atm-20-3090</idno>
	</analytic>
	<monogr>
		<title level="j">Ann. Transl. Med</title>
		<imprint>
			<biblScope unit="volume">2021</biblScope>
			<biblScope unit="page">732</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b123">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">Z</forename><surname>TÃ¼mer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">B</forename><surname>MÃ¸ller</surname></persName>
		</author>
		<author>
			<persName><surname>Menkes Disease</surname></persName>
		</author>
		<idno type="DOI">10.1038/ejhg.2009.187</idno>
	</analytic>
	<monogr>
		<title level="j">Eur. J. Hum. Genet</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="511" to="518" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b124">
	<analytic>
		<title level="a" type="main">Kinky Hair Disease: Twenty Five Years Later</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Menkes</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0387-7604(88)80074-3</idno>
	</analytic>
	<monogr>
		<title level="j">Brain Dev</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="77" to="79" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b125">
	<monogr>
		<title level="m" type="main">Menkes Kinky Hair Disease</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">K</forename><surname>Ramani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Parayil Sankaran</surname></persName>
		</author>
		<ptr target="https://www.ncbi.nlm.nih.gov/books/NBK560917/" />
		<imprint>
			<date type="published" when="2023-11-27">27 November 2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b126">
	<analytic>
		<title level="a" type="main">Molecular Pathogenesis of Wilson and Menkes Disease: Correlation of Mutations with Molecular Defects and Disease Phenotypes</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Bie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Muller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wijmenga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">W J</forename><surname>Klomp</surname></persName>
		</author>
		<idno type="DOI">10.1136/jmg.2007.052746</idno>
	</analytic>
	<monogr>
		<title level="j">J. Med. Genet</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="673" to="688" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b127">
	<analytic>
		<title level="a" type="main">Copper Transport and Disease: What Can We Learn from Organoids?</title>
		<author>
			<persName><forename type="first">H</forename><surname>Pierson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lutsenko</surname></persName>
		</author>
		<idno type="DOI">10.1146/annurev-nutr-082018-124242</idno>
	</analytic>
	<monogr>
		<title level="j">Annu. Rev. Nutr</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="75" to="94" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b128">
	<monogr>
		<ptr target="https://www.ninds.nih.gov/health-information/disorders/menkes-disease" />
		<title level="m">Menkes Disease|National Institute of Neurological Disorders and Stroke</title>
		<imprint>
			<date type="published" when="2023-11-27">27 November 2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b129">
	<analytic>
		<title level="a" type="main">The Molecular Mechanisms of Copper Metabolism and Its Roles in Human Diseases</title>
		<author>
			<persName><forename type="first">J</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Peng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Li</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00424-020-02412-2</idno>
	</analytic>
	<monogr>
		<title level="j">Pflugers Arch</title>
		<imprint>
			<biblScope unit="volume">472</biblScope>
			<biblScope unit="page" from="1415" to="1429" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b130">
	<analytic>
		<title level="a" type="main">Role of Copper Transporters in Copper Homeostasis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Prohaska</surname></persName>
		</author>
		<idno type="DOI">10.1093/ajcn/88.3.826S</idno>
	</analytic>
	<monogr>
		<title level="j">Am. J. Clin. Nutr</title>
		<imprint>
			<biblScope unit="volume">88</biblScope>
			<biblScope unit="page" from="826S" to="829" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b131">
	<analytic>
		<title level="a" type="main">A Copper Chaperone for Superoxide Dismutase That Confers Three Types of Copper/Zinc Superoxide Dismutase Activity in Arabidopsis</title>
		<author>
			<persName><forename type="first">C.-C</forename><surname>Chu</surname></persName>
		</author>
		<idno type="DOI">10.1104/pp.105.065284</idno>
	</analytic>
	<monogr>
		<title level="j">J. Plant Physiol</title>
		<imprint>
			<biblScope unit="volume">139</biblScope>
			<biblScope unit="page" from="425" to="436" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b132">
	<analytic>
		<title level="a" type="main">Copper Uptake by DMT1: A Compensatory Mechanism for CTR1 Deficiency in Human Umbilical Vein Endothelial Cells</title>
		<author>
			<persName><forename type="first">C</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>James Kang</surname></persName>
		</author>
		<idno type="DOI">10.1039/c5mt00097a</idno>
	</analytic>
	<monogr>
		<title level="j">Metallomics</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="1285" to="1289" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b133">
	<analytic>
		<title level="a" type="main">Copper Binding to the Alzheimer&apos;s Disease Amyloid Precursor Protein</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">K</forename><surname>Kong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">-W</forename><surname>Miles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Crespi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A N</forename><surname>Morton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Ng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename><surname>Barnham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Mckinstry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Cappai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Parker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename></persName>
		</author>
		<idno type="DOI">10.1007/s00249-007-0234-3</idno>
	</analytic>
	<monogr>
		<title level="j">Eur. Biophys. J</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="269" to="279" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b134">
	<analytic>
		<title level="a" type="main">Metallothionein Is Crucial for Safe Intracellular Copper Storage and Cell Survival at Normal and Supra-Physiological Exposure Levels</title>
		<author>
			<persName><forename type="first">L</forename><surname>Tapia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gonzalez-Aguero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Cisternas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Suazo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Cazmbiazo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Uauy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gonzalez</surname></persName>
		</author>
		<idno type="DOI">10.1042/bj20031174</idno>
	</analytic>
	<monogr>
		<title level="j">Biochem. J</title>
		<imprint>
			<biblScope unit="volume">378</biblScope>
			<biblScope unit="page" from="617" to="624" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b135">
	<analytic>
		<title level="a" type="main">Copper Activates Metallothionein Gene Transcription by Altering the Conformation of a Specific DNA Binding</title>
		<author>
			<persName><forename type="first">P</forename><surname>FÃ¼rst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hackett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hamer</surname></persName>
		</author>
		<idno type="DOI">10.1016/0092-8674(88)90229-2</idno>
	</analytic>
	<monogr>
		<title level="j">Protein. Cell J</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="705" to="717" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b136">
	<analytic>
		<title level="a" type="main">Functional Understanding of the Versatile Protein Copper Metabolism MURR1 Domain 1 (COMMD1) in Copper Homeostasis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Fedoseienko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bartuzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Van De Sluis</surname></persName>
		</author>
		<idno type="DOI">10.1111/nyas.12353</idno>
	</analytic>
	<monogr>
		<title level="j">Ann. N. Y. Acad. Sci</title>
		<imprint>
			<biblScope unit="volume">1314</biblScope>
			<biblScope unit="page" from="6" to="14" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b137">
	<analytic>
		<title level="a" type="main">COMMD1 Expression Is Controlled by Critical Residues That Determine XIAP Binding</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">N</forename><surname>Maine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Mao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Muller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Komarck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">W J</forename><surname>Klomp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Burstein</surname></persName>
		</author>
		<idno type="DOI">10.1042/BJ20080854</idno>
	</analytic>
	<monogr>
		<title level="j">Biochem. J</title>
		<imprint>
			<biblScope unit="volume">417</biblScope>
			<biblScope unit="page" from="601" to="609" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b138">
	<analytic>
		<title level="a" type="main">Cell Death Regulation Meets Copper Homeostasis</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Mufti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Burstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Duckett</surname></persName>
		</author>
		<author>
			<persName><surname>Xiap</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.abb.2007.01.033</idno>
	</analytic>
	<monogr>
		<title level="j">Arch. Biochem. N.Y</title>
		<imprint>
			<biblScope unit="volume">463</biblScope>
			<biblScope unit="page" from="168" to="174" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b139">
	<analytic>
		<title level="a" type="main">Copper chaperones: Personal escorts for metal ions</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">S</forename><surname>Field</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Luk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">C</forename><surname>Culotta</surname></persName>
		</author>
		<idno type="DOI">10.1023/A:1021202119942</idno>
	</analytic>
	<monogr>
		<title level="j">J. Bioenerg. Biomembr</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="373" to="379" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b140">
	<analytic>
		<title level="a" type="main">Zn-Superoxide Dismutase Is Lower and Copper Chaperone CCS Is Higher in Erythrocytes of Copper-Deficient Rats and Mice</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">C</forename><surname>West</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Prohaska</surname></persName>
		</author>
		<author>
			<persName><surname>Cu</surname></persName>
		</author>
		<idno type="DOI">10.1177/153537020422900807</idno>
	</analytic>
	<monogr>
		<title level="j">Exp. Biol. Med</title>
		<imprint>
			<biblScope unit="volume">229</biblScope>
			<biblScope unit="page" from="756" to="764" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b141">
	<analytic>
		<title level="a" type="main">The Human Cytochrome c Oxidase Assembly Factors SCO1 and SCO2 Have Regulatory Roles in the Maintenance of Cellular Copper Homeostasis</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Leary</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Cobine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Kaufman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G.-H</forename><surname>Guercin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mattman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Palaty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Lockitch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Winge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Rustin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Horvath</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cmet.2006.12.001</idno>
	</analytic>
	<monogr>
		<title level="j">Cell Metab</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="9" to="20" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b142">
	<analytic>
		<title level="a" type="main">Structure of the Ctr1 Copper Trans&apos;PORE&apos;ter Reveals Novel Architecture</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Nose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Rees</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Thiele</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.tibs.2006.09.003</idno>
	</analytic>
	<monogr>
		<title level="j">Trends Biochem. Sci</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="604" to="607" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b143">
	<analytic>
		<title level="a" type="main">Human Copper Transporter 2 Is Localized in Late Endosomes and Lysosomes and Facilitates Cellular Copper Uptake</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">V</forename><surname>Van Den Berghe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Folmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">E</forename><surname>MalingrÃ©</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Van Beurden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Klomp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Van De Sluis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Merkx</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Berger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">W</forename><surname>Klomp</surname></persName>
		</author>
		<idno type="DOI">10.1042/BJ20070705</idno>
	</analytic>
	<monogr>
		<title level="j">Biochem. J</title>
		<imprint>
			<biblScope unit="volume">407</biblScope>
			<biblScope unit="page" from="49" to="59" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b144">
	<analytic>
		<title level="a" type="main">Expression Is Increased in Monocytes and Erythrocytes of Young Men during Zinc Supplementation</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">K</forename><surname>Sullivan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">R</forename><surname>Burnett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Cousins</surname></persName>
		</author>
		<author>
			<persName><surname>Metallothionein</surname></persName>
		</author>
		<idno type="DOI">10.1093/jn/128.4.707</idno>
	</analytic>
	<monogr>
		<title level="j">J. Nutr</title>
		<imprint>
			<biblScope unit="volume">128</biblScope>
			<biblScope unit="page" from="707" to="713" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b145">
	<analytic>
		<title level="a" type="main">How Reliable and Robust Are Current Biomarkers for Copper Status?</title>
		<author>
			<persName><forename type="first">R</forename><surname>Danzeisen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Araya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Harrison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Keen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Solioz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Thiele</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Mcardle</surname></persName>
		</author>
		<idno type="DOI">10.1017/S0007114507798951</idno>
	</analytic>
	<monogr>
		<title level="j">Br. J. Nutr</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="page" from="676" to="683" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b146">
	<monogr>
		<title level="m" type="main">The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods</title>
		<imprint>
			<publisher>Disclaimer/Publisher&apos;s Note</publisher>
		</imprint>
	</monogr>
	<note>instructions or products referred to in the content</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
